

Ethyl 2-cyano-2-(2-nitrobenzenesulfonyloxyimino)acetate (o-NosylOXY): A Recyclable Coupling Reagent for Racemization free Synthesis of Peptide, Amide, Hydroxamate and Ester

Dharm Dev, Nani Babu Palakurthy, Kishore Thalluri, Jyoti Chandra, and Bhubaneswar Mandal

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/jo500292m • Publication Date (Web): 21 May 2014

Downloaded from <http://pubs.acs.org> on May 25, 2014

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Ethyl 2-cyano-2-(2-nitrobenzenesulfonyloxyimino)acetate (*o*-NosyIOXY): A Recyclable Coupling Reagent for Racemization free Synthesis of Peptide, Amide, Hydroxamate and Ester

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46


Dharm Dev, Nani Babu Palakurthy, Kishore Thalluri, Jyoti Chandra, and Bhubaneswar Mandal*

47
48
49
50
51
52
53
54
55
56
57
58
59
60

Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati. Assam.

India-781039

bmandal@iitg.ernet.in




ABSTRACT: Ubiquitousness of amide and ester functionality makes coupling reactions extremely important. Although numerous coupling reagents are available, methods of preparation of the common and efficient reagents are cumbersome. Those reagents generate substantial amount of chemical waste and lack recyclability. Ethyl 2-cyano-2-(2-nitrobenzenesulfonyloxyimino)acetate (*o*-NosyIOXY), the first member of a new generation of

1
2
3
4 coupling reagents, is found for which byproducts can be easily recovered and reused for the
5
6 synthesis of the same reagent making the method more environment friendly and cost effective.
7
8 Synthesis of amides, hydroxamates, peptides, and esters using this reagent is described.
9
10 Synthesis of the difficult sequences, for example, islet amyloid polypeptide (22-27) fragment
11
12 (with a C-terminal Gly, H-Asn-Phe-Gly-Ala-Ile-Leu-Gly-NH₂) and acyl carrier protein (65-74)
13
14 fragment (H-Val-Gln-Ala-Ala-Ile-Asp-Tyr-Ile-Asn-Gly-OH), following solid phase peptide
15
16 synthesis (SPPS) protocol and Amyloid β (39-42) peptide (Boc-Val-Val-Ile-Ala-OMe) following
17
18 solution phase strategy is demonstrated. The remarkable improvement is noticed with respect to
19
20 reaction time, yield, and retention of stereochemistry. A mechanistic investigation and
21
22 recyclability are also described.
23
24
25
26
27
28
29
30

31 INTRODUCTION

32
33
34 Amide and ester functionality are present in most of the natural products as well as
35
36 pharmaceutical compounds.¹ Therefore, coupling reactions, which comprise activation of
37
38 carboxylic acids into an activated form that undergo acylation to produce esters, amides, and
39
40 peptides, are extremely important for academia and industry. Numerous coupling reagents have
41
42 been developed and commercialized including carbodiimides, phosphonium, and uronium/
43
44 aminium salts.² Most of them engage the benzotriazole or azabenzotriazole ring system as an
45
46 important fragment of their structure, which is subsequently transformed into a good leaving
47
48 group.³ After two decades of domination of benzotriazole-based chemistry, with the pioneering
49
50 work of Albericio et al., a new class of peptide coupling reagents, that is, ethyl 2-cyano-2-
51
52 (hydroxyimino)acetate (Oxyma) based reagents, have been introduced.⁴ Oxyma is superior to its
53
54
55
56
57
58
59
60


1
2
3 counterparts as racemisation suppressant and environment friendly reagent.⁵ Nevertheless,
4 existing popular coupling reagents (HOBt based coupling reagents as well as Oxyma based
5 coupling reagents) still suffer from three major drawbacks: (a) They generate lot of chemical
6 waste. For example, carcinogenic hexamethylphosphoramide (HMPA) and explosive
7 hydroxybenzotriazole (HOBt) are generated as by-products, when benzotriazol-1-
8 yloxytris(dimethylamino)phosphoniumhexafluorophosphate (BOP) is used as coupling reagent.⁶
9 Similarly, a urea derivative as well as HOBt is generated when *N*-(benzotriazol-1-yl)-1,1,3,3-
10 tetramethyluroniumhexafluoro phosphate (HBTU) is used.⁷ (b) Preparation protocols of these
11 reagents involve harsh conditions and toxic reagents. For example, HBTU is synthesized using
12 phosgene (inflammable, causes skin damage) and HOBt (explosive) in carbon tetrachloride, a
13 carcinogenic solvent.⁷ Similarly, 1-[(1-(cyano-2-ethoxy-2-oxoethylideneamino-oxo)-
14 dimethylamino-morpholinomethylene)] methanaminium hexafluorophosphate (COMU), an
15 Oxyma based coupling reagent, is also synthesized using phosgene. (c) Furthermore, recycling
16 those reagents may be cumbersome. Thus, they are not environment friendly and cost effective.
17 Therefore, invention of an ideal coupling reagent with highest level of efficacy but devoid of
18 epimerization tendency at the same time environment friendly and recyclable still remains a
19 challenge. We described herein a coupling reagent, Ethyl 2-cyano-2-(2-nitrobenzenesulfonyloxyimino)acetate (*o*-NosylOXY, **I**), which have similar efficiency but devoid of the said
20 drawbacks.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



55
56 **Figure 1.** Ethyl 2-cyano-2-(2-nitrobenzenesulfonyloxyimino)acetate (*o*-NosylOXY, **I**)
57
58
59
60

RESULTS AND DISCUSSION

The reagent **I**, *o*-NosyloXY, was synthesized easily by the reaction between *ortho*-nitrobenzenesulfonyl chloride and Oxyma in presence of diisopropylethylamine (DIPEA) under nitrogen atmosphere.⁸ Reagent **I** is stable at room temperature (25 °C) and can be stored for long time. A time dependent HPLC and ¹HNMR studies of **I** indicated no change until 20 days (Supporting Information, Figure S112-S117). Its coupling efficiency was investigated using the reaction between phenyl acetic acid and benzyl amine, DCM as a solvent (Scheme 1). Very good yield (91 %) of the product, *N*-benzyl-2-phenylacetamide, was obtained in 2 h at room temperature. Sulfonamide formation is an expected side reaction for such reagents. We performed a model reaction between phenylacetic acid and benzyl amine using *o*-NosyloXY in presence of DIPEA in DCM without pre-activation. After completion of the reaction, we found 40 % yield of *N*-benzyl-2-nitrobenzenesulfonamide and 50 % yield of *N*-benzyl-2-phenylacetamide. To avoid such sulfonamide formation, we used 3-5 min pre-activation.



Scheme 1. Synthesis of amides and peptides using reagent **I**.

For solvent optimization we screened several solvents for the coupling reaction between phenyl acetic acid and benzyl amine employing reagent **I**, and DCM was found to be the best solvent (Table 1). Therefore, DCM was used for amidation, esterification and hydroxamate synthesis.

Table 1. Solvent screening experiments

Entry ^a	Solvent	Yield (%) ^b	Time (h)
1	Acetonitrile	67	8
2	DMSO	56	11
3	THF	48	13
4	DMF	85	3
5	DCM	91	2.2
6	Ethyl acetate	70	5
7	Chloroform	78	3

^aPerformed with phenylacetic acid (136 mg 1 equiv), Reagent **I** (1 equiv), DIPEA (2.2 equiv), benzyl amine (1 equiv), room temperature (25 °C). ^bYields refer to the isolated yield after column chromatography.

For racemization studies, we synthesized Z-DL-Phe-L-Ala-OMe and Z-L-Phe-L-Ala-OMe using **I** and compared their HPLC profiles (Figure 2) to estimate the amount of racemization caused by the coupling reagent. Appearance of the twin peak in the HPLC profile of Z-DL-Phe-L-Ala-OMe corresponds to the two diastereomeric products, whereas, presence of the single peak in that of Z-L-Phe-L-Ala-OMe demonstrates virtually no racemization occurred during the synthesis. Comparison of the ¹H and ¹³C NMR spectra of these dipeptides also supports the hypothesis (supporting information, Figure S29-S32). We found two doublets in ¹H NMR at $\delta = 1.32$ and 1.21 ppm and similarly four peaks at $\delta = 173.0$, 172.9 , 170.9 and 170.7 ppm in ¹³C NMR of Z-DL-Phe-L-Ala-OMe, which indicate the presence of two diastereomers. Whereas, we found one doublet at $\delta = 1.32$ ppm in the ¹H NMR and two peaks at $\delta = 173.0$ and 170.7 ppm in ¹³C NMR for Z-L-Phe-L-Ala-OMe indicating the presence of one diastereomer.




Figure 2. Comparison of the HPLC profiles of Z-DL-Phe-L-Ala-OMe (left panel) and Z-L-Phe-L-Ala-OMe (right panel) (C18 reverse phase analytical column, 5 μm , 25 cm \times 4.6 mm, linear gradient of 0-80 %, 0-7 min. then 80-100 % upto 20 min., CH_3CN in H_2O with 0.1% formic acid)

However, suppression of epimerization is known to occur for the presence of the *N*-terminal urethane protecting group.⁹ To remove that doubt, we synthesized a tripeptide, Z-Gly-Phe-Val-OMe (entry 18, Table 3), via coupling of Z-Gly-Phe-OH and H-Val-OMe in solution using **I**, estimated the amount of racemization and compared that with reported data obtained for the synthesis of the same tripeptide using other coupling reagents, such as, HBTU (*N*-[(1*H*-benzotriazol-1-yl)(dimethylamino) methylene] *N*-methylmethanaminiumhexafluorophosphate-*N*-oxide), HATU (*N*-[(dimethylamino)-1*H*-1,2,3-triazolo[4,5-*b*]pyridin-1-yl-methylene)-*N*-methylmethanaminium hexafluorophosphate-*N*-oxide), HDMB (1-((dimethylamino)(morpholino)methylene)-1*H*-benzotriazoliumhexafluorophosphate-3-oxide) and HDMA (1-((dimethylamino)-(morpholino)methylene)-1*H* [1,2,3]triazolo[4,5-

b]pyridiniumhexafluorophosphate3-oxide).¹⁰ No racemization could be observed, when reagent **I** was used, however, epimerization was noted for other reagents (Table 2).

Table 2. Comparison of yield and racemization tendency for the formation of Z-Gly-Phe-Val-OMe using *o*-NosylOXY (**I**) with the reported¹⁰ results using various coupling reagents.

Entry	Coupling Reagent	Yield (%)	Racemization (%)
1	HBTU	89	5.9
2	HATU	90	1.6
3	HDMB	90	2.9
4	HDMA	90	0.7
5	<i>o</i> -NosylOXY	91	n. d. ^a























^aNo racemization could be detected by the ¹H and ¹³C NMR spectra and the HPLC profile (Supporting Information, Figures S39- S40 and S128) within the limit of our experimental condition.

With the suitable conditions in hand, applicability of this method was explored with various carboxylic acids and amines (Table 3). Interestingly, the reaction worked well with aromatic and aliphatic carboxylic acids (entry 1-4, Table 3) as well as amino acids (entry 5-18). Even in case of less nucleophilic amine, aniline (entry 4), the yield was found to be remarkably good. However, repeated attempt of the reaction with 4-nitroaniline failed. It tolerates common amine protecting groups including Fmoc and Cbz. Furthermore, the reaction worked well for sterically hindered amino acids, e.g. Val (entries 10) and Aib (entries 16 and 17), as carboxylic acid component as well as tertiary butyl amine (entry 6), Aib (entry 7), and Val (entry 18) as amine component, which are known to be difficult for coupling. In all the cases, the yields were


1
2
3 excellent and comparable with other reported common coupling reagents¹¹ with no observed
4 racemization.
5
6

7
8 We also performed the reaction between Fmoc-Phe-OH and NH₂-Ala-OMe in the presence of *o*-
9 nitrobenzenesulfonyl chloride as a coupling reagent. In this case, we obtained dipeptide, Fmoc-
10 Phe-Ala-OMe, with 65 % yield and sulfonamide, *o*-nitrobenzenesulfonamide of methyl ester of
11 alanine, with 10% yield. About 10 % racemization was observed in the HPLC profile of the
12 dipeptide (Supporting Information, Figure S130-S132). This demonstrates the utility of the
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Oxyma part in reagent I.

Table 3. Synthesis of various amides and peptides under optimized condition using reagent I.

Entry ^a	Acid	Amine	Yield (%) ^b
1			88
2			91
3			82
4			86
5			89
6			81
7			80
8			91
9			89
10			87
11			93
12			87


continue...



















^aPerformed with Acid (1 equiv), Reagent I (1 equiv), DIPEA (2.2 equiv), Amine (1 equiv), room temperature (25 °C), 2-3 h. ^bYields were referred to the isolated yields after column chromatography.

Hydroxamates of amino acids are another interesting class of compounds which possess a broad spectrum of medicinal properties.¹² Therefore, we wanted to adopt the present methodology for the synthesis of such important drug candidates.

Table 4. Synthesis of hydroxamates using **I**



R¹ = aryl, alkyl or fmoc-amino acid

Entry ^a	Acid	O-benzylhydroxylamine	Yield (%) ^b
1			92
2			90
3			89
4			91
5			88
6			84
7			82
8			81

^aPerformed with Acid (1 equiv), Reagent I (1 equiv), DIPEA (2.2 equiv), *O*-benzylhydroxylamine (1 equiv), room temperature (25 °C), 2-3 h. ^bYields were referred to the isolated yields after column chromatography.

Our initial trials of coupling with model substrate, i.e. benzoic acid with *O*-benzyl hydroxylamine using reagent I yielded the desired product in very good yield (91%, entry 1, Table 4). Then it was further extended to a variety of amino acids with varying side chain complexity (entry 4-8, Table 4). Very good yields (81 to 92 %) were obtained on stirring at room temperature (25 °C) for 2-3 hours.




Figure 3. Sequences of peptides synthesised: (a) NFGAILG and (b) VQAAIDYING using SPPS, HPLC and ESI-MS spectra (see supporting information, Figure S167-168); (c) Boc-VVIA-OMe in solution.

We further envisaged to use reagent **I** for long chain peptide synthesis. As target, we took IAPP (22-27) peptide (IAPP, Islet Amyloid Poly Peptide: H-Asn-Phe-Gly-Ala-Ile-Leu-Gly-NH₂, Figure 3a)¹³ and ACP (65-74) peptide fragment (ACP, Acyl Carrier Protein: H-Val-Gln-Ala-Ala-Ile-Asp-Tyr-Ile-Asn-Gly-OH, Figure 3b).¹¹ Both of them are known as difficult sequences for synthesis as they contain many hydrophobic amino acids and undergo conformational change resulting in aggregation during the synthesis.

1
2
3
4
5
6 We achieved the synthesis of these peptides in very good yield (40% for the IAPP (22-27) and
7
8 50 % for the ACP (65-74) fragment after chromatographic purification, with respect to resin
9
10 loading) by stepwise coupling of constituent amino acids on rink amide MBHA resin using **I** as a
11
12 coupling reagent following Fmoc/tBu orthogonal protection technique based SPPS (Solid Phase
13
14 Peptide Synthesis) method. 3.2 fold excess of the Fmoc amino acids and 3 fold excess of the
15
16 coupling reagents were used for each coupling step and gently rotated. Care should be taken not
17
18 to take more amount of the coupling reagent than that of the *N*-protected amino acid, unlike other
19
20 coupling reagents, for avoiding truncation by sulfonamide formation. Although reagent **I**
21
22 generates higher yield in DCM than in DMF (Table 1), we used DMF as solvent for SPPS, as
23
24 DMF is more commonly used in SPPS. Couplings were accomplished smoothly in 2 hours,
25
26 which were confirmed by Kaiser test. A small amount of resin was taken after each coupling and
27
28 cleaved the peptide from resin using TFA/DCM/H₂O mixture, precipitated using cold ether and
29
30 injected in analytical HPLC for examining the purity at each step. Each time single peak was
31
32 observed; eluent was collected and injected in ESI-MS for confirming the mass of the peptide
33
34 fragment. The HPLC retention times and ESI-MS data for each fragment during the synthesis of
35
36 IAPP (22-27) are mentioned in Table S1 in Supporting Information. The HPLC profiles and ESI-
37
38 MS spectra of the purified peptides are also provided in supporting information (Figure S153 and
39
40 154). Quality of the crude peptide also was excellent. As an example, that for peptide ACP (65-
41
42 74) was compared with the reported data (Table 5).¹¹ Quality of the crude IAPP (22-27) peptide
43
44 fragment synthesized using **I** as coupling reagent was also very good (Supporting Information,
45
46 Figure S151). We also synthesized Boc-Val-Val-Ile-Ala-OMe, the C-terminal fragment of the
47
48 Amyloid β peptide.¹⁴ This is also a hydrophobic difficult sequence bearing huge steric
49
50
51
52
53
54
55
56
57
58
59
60


hinderance (Figure 3c). A Boc-chemistry based stepwise coupling was performed in DCM following solution phase methodology. Yield was good (78%, after five steps with respect to starting Boc-Ile-OH) and HPLC chromatogram of the crude peptide (Supporting Information, Figure S137) was as good as a purified peptide.

Table 5. Comparative study of the purity of crude ACP (65-74) by TBTU, HATU, TBCR and *o*-NosylOXY

Coupling reagent	Purity of crude ACP (65-74) [%]
TBTU	69
HATU	87
TBCR	84
<i>o</i> -NosylOXY	90 ^a

^a90% purity of the crude peptide could be detected by HPLC (supporting information Figure S165).























Soon completion of the establishment of the applicability of the coupling reagent **I** for the synthesis of amides, hydroxamates and peptides, we investigated its efficiency for esterification (Scheme 2). In spite of the numerous methodologies for the coupling reaction of alcohols and carboxylic acids, it is still desired to develop an efficient coupling reagent for the said transformation that is racemization free, with high yields for complicated substrates, clean isolation of the products and most importantly, recyclable. Esterification using **I** addressed most of these difficulties that were associated with the rest of the methodologies.



Scheme 2. Synthesis of ester under optimized condition

As a model reaction, we took phenyl acetic acid (1 mmol), in dichloromethane and added diisopropyl ethyl amine (1.1 mmol) to it. *o*-NosyIOXY (1 mmol) was added to this mixture at room temperature (25 °C) with stirring. After 5 min, benzyl alcohol (1 mmol) and DIPEA (1.1 mmol) was added. After 2 h, the reaction was found to be complete and furnished the desired product in very good yield (92 %).

Table 6. Scope of esterification using reagent I

Entry ^a	Acid	Alcohol	Yield(%) ^b
1			87
2			82
3			90
4			81
5			92
6			84
7			89
8			85
9			91
10			90
11			89
12			91
13			87

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

^aPerformed with Acid (1 equiv), Reagent I (1 equiv), DIPEA (2.2 equiv), Alcohol (1 equiv), room temperature (25 °C), 2-3.5 h. ^bYields refer to the isolated yields after column chromatography.

After standardization of the reaction conditions, we investigated the generality of the present protocol applying it to various alcohols and carboxylic acids. The reaction of phenyl acetic acid with varieties of aromatic (entry 1-4, Table 6) and aliphatic (entry 5-7) alcohols worked well. From the observation of the yields of entries 1-4, it was evident that the presence of electron donating group on phenol retards the reaction and thereby yields lesser product than its counterparts, which is in agreement with the stability of the phenoxide ions. The reaction went well with secondary (entry 7) and tertiary alcohol (entry 6).

The present protocol was successfully applied for the synthesis of biologically active esters also. The aliphatic carboxylic acids (entry 1-3, Table 7) worked well. The mentioned electromeric affect holds true for these reactions as well. In case of salicylic acid, i.e. entry 4, the reaction was chemoselective and produced 4-nitro-benzyl ester of salicylic acid as a major product; although two nucleophilic attacks were logically possible. Self-condensation was very less due to the lesser nucleophilicity of the hydroxyl group of the salicylic acid than that of the *p*-nitrobenzyl alcohol. Phenolic acids have been esterified with excellent chemoselectivity in presence of strong protic acids (Fischer esterification), but harsh reaction conditions and excess of alcohol was required to drive the reaction to a satisfactory degree of conversion,¹⁵ whereas, it worked smoothly in the present protocol, which is milder. Furthermore, in case of entry 5 and 6 (Table 7) the product observed was the ester alone, not the corresponding amide. Various aliphatic primary alcohols (entries 4-11, Table 7) and a secondary alcohol (entry 7) were subjected to the reaction conditions and the yield was good (82-90 %).


Table 7. Synthesis of various carboxylic esters using **I**.

Entry ^a	Acid	Alcohol	Time (h)	Yield (%) ^b
1			4.0	86
2			2.5	92
3			3.0	91
4			2.0	82
5			2.5	86
6			3.0	90
7			3.0	90
8			3.15	89
9		CH ₃ OH	3.0	87
10			2.5	90
11			2.5	89


^aPerformed with Acid (1 equiv), Reagent I (1 equiv), DIPEA (2.2 equiv), Alcohol (1 equiv), room temperature (25 °C). ^bYields refer to the isolated yields after column chromatography.

Even amino acids (entry 9-11, Table 7) retained the same reactivity towards this reaction. In order to estimate the extent of racemization, we initially synthesized Boc-DL-Phe-OBn using our

1
2
3
4 protocol and passed through a chiral column. Two distinct peaks, corresponding to the two
5
6 enantiomers, were observed in HPLC chromatogram (Figure 4, Left panel). Next, we synthesized
7
8 Boc-L-Phe-OBn following the same strategy. Chromatographic signature of Boc-L-Phe-OBn
9
10 reveals only one peak corresponding to the enantiopure product (Figure 4, Right panel).
11
12 Therefore, it was inferred that the present protocol does not cause any detectable racemization.
13
14




15
16
17
18
19
20
21
22
23
24
25
26
27
28 **Figure 4.** HPLC chromatogram of Boc-D,L-Phe-OBn (Left panel) and Boc-L-Phe-OBn (Right
29
30 panel, CHIRAL PAK^R AS-H column, 5 μ m, 2.1 \times 150 mm, an isocratic gradient of 10%
31
32 isopropanol in hexane was used).
33
34



56 **Scheme 3.** Plausible pathways for the condensation
57
58
59
60

1
2
3
4 A plausible mechanism is depicted in Scheme 3. Initially, the nucleophile generated by the
5 deprotonation of the carboxylic acid in presence of DIPEA attacks the sulfonyl centre of **I**.
6
7
8 Expulsion of the resonance stabilized Oxyma anion **II** results in the mixed anhydride **III**. Further
9
10 nucleophilic attack of **II** on the carbonyl carbon of **III** and expulsion of the sulfonic acid **IV**
11
12 results in the formation of the intermediate **V**, the activated Oxyma ester of the carboxylic acid.
13
14
15 **V** undergoes nucleophilic substitution to produce the corresponding ester or amide. Isolation and
16
17 complete characterization using ^1H NMR and ^{13}C NMR (Supporting Information, Figure S1-S2)
18
19 and XRD analysis of the intermediate **V** was achieved (Supporting Information, Figure S169).
20
21
22 However, the added nucleophile (amine or alcohol) may also react with the intermediate **III**. But,
23
24 in that case, sulfonamide also may get generated as byproduct and racemization of the product is
25
26 expected, as it was observed when the reaction was performed without pre-activation or using *o*-
27
28 nitrobenzenesulfonyl chloride. A 3-5 min pre-activation precludes that possibility by increasing
29
30 the population of the intermediate **V** in the reaction mixture.
31
32
33

34
35 The product as well as by-products Oxyma (**II**) and 2-nitrobenzene sulfonic acid (**IV**) were
36
37 recovered easily. After completion of the reaction (entry 2, Table 4), the reaction mixture was
38
39 diluted with ethyl acetate and washed with 5% citric acid solution (3×5 ml). Concentrated
40
41 organic layer was directly purified by a silica gel column chromatography. The product and
42
43 byproducts were eluted with specific eluents. Purity of the recovered **II** and **IV** was as good as
44
45 the commercial samples (supporting information Figure S103-S105). The recovered sulfonic
46
47 acid was chlorinated by heating on 60 °C for 1.5 h in toluene with a small amount of DMF using
48
49 thionyl chloride. Pure sulfonyl chloride, obtained in this way, was transformed to **I** by stirring
50
51 with Oxyma in basic medium (DIPEA).
52
53
54
55
56
57
58
59
60



24
25
26
27
28
29

Scheme 4. Recyclability of coupling reagent **I**. ^aYield of the regenerated **I** from the recovered **II** and **IV** was calculated with respect to the initial amount of **I** used in the reaction.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

To the best of our knowledge, only one such recyclable coupling reagent is reported, which is a hypervalent iodine-III reagent, iodosodilactone, and it works in association with DMAP and PPh₃.¹⁶ Dipeptide formation with this combination of reagents usually takes 8 h under heating condition (60 °C). On the other hand, it takes only 1 h at room temperature (25 °C) by our method. Moreover, stoichiometric amount of triphenyl phosphine oxide is generated with iodosodilactone/DMAP/PPh₃, whereas the present method does not leave any solid waste to the environment.

CONCLUSION

We have introduced a new and efficient coupling reagent, *o*-NosylOXY (**I**), for the synthesis of amide, hydroxamate, peptide and ester. The present method is associated with the following important features: 1) apparently complete retention of stereochemistry, 2) applicability to both solution and solid phase synthesis of large peptides with difficult sequences, 3) ease of preparation of the reagent, 4) works under ambient and milder conditions. A plausible mechanism is suggested and an intermediate could be isolated and fully characterized which supports that. Most importantly, the reagent is recyclable, therefore, cost effective and environment friendly. All these features makes this reagent useful for industry and academia in the context of condensation chemistry.

EXPERIMENTAL SYSTEM

General consideration:

All reagents were purchased from commercial sources and were used without any further purification unless mentioned otherwise. *o*-nitrobenzenesulfonyl chloride is freshly recrystallized before use. Dichloromethane is distilled and dried using standard procedure. Melting points were uncorrected. Thin layer chromatograms were run on glass plates coated with silica gel G for TLC, using solvent systems EtOAc/Hexane. Compounds were purified by column chromatography using Silica Gel (60-120 mesh) with EtOAc/Hexane (of specific proportion as required) as an eluent. ¹H NMR (400 MHz and 600 MHz) and ¹³C NMR (100 MHz and 150 MHz) were recorded using CDCl₃ as solvent. Chemical shifts (δ) are reported in parts per million (ppm), internal reference (0.05% to 1 %) tetramethylsilane. Coupling constants (*J*) are reported in Hz singlet (s), doublet (d), triplet (t), doublet of doublet (dd), multiplet (m), or broad (br).

1
2
3 High resolution mass spectra were recorded on a Q-TOF ESI-MS instrument and a Q-TOF
4 LC/MS system; HPLC analysis was carried out with either a C8 (5 μ m, 3.5 \times 150 mm) or a C18
5 (5 μ m, 4.6 \times 250 mm) reverse phase column and a chiral column (5 μ m, 2.1 \times 150 mm) coupled
6 to a UV detector. HPLC grade solvents were used for HPLC analysis. IR spectra were recorded
7 on a IR spectrometer; X-ray data were collected on a diffractometer equipped with a CCD area
8 detector using Mo. Data for previously reported compounds (cited) matched well with our
9 observed data.
10
11
12
13
14
15
16
17
18
19

20
21 **Procedure for Synthesis of Coupling Reagent Ethyl 2-cyano-2-(2-nitrobenzenesulfonyloxy**
22 **imino) acetate (*o*-NosylOXY, I):**
23
24

25
26 DIPEA (0.87 ml, 5 mmol, 1 equiv) was added to a solution of Oxyma (710 mg, 5 mmol, 1
27 equiv) in 2 ml of DCM under nitrogen. The reaction mixture was cooled up to 0 $^{\circ}$ C and followed
28 by dropwise addition of 2-nitrobenzenesulfonyl chloride (1108 mg, 1 mmol, 1 equiv) for 30 min.
29 The reaction mixture was stirred for another 2 h at room temperature (25 $^{\circ}$ C). After completion
30 of the reaction, the reaction mixture was diluted with 10 ml of DCM and washed with 5% of HCl
31 (3 \times 5 ml). Finally organic layer dried by anhydrous CaCl₂ and recrystallized with hexane. R_f =
32 0.50 (EtOAc:Hexane, 1:4), Yield 1308 mg, 80 %; colorless crystalline solid; ¹H NMR (400
33 MHz, CDCl₃): δ 8.26-8.24 (d, J = 8.0 Hz, 1H), 7.95-7.90 (m, 1H), 7.89-7.84 (m, 2H), 4.45-4.40
34 (q, 2H), 1.39-1.36 (t, J = 8.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 155.5, 148.6, 137.3,
35 133.3, 132.9, 132.7, 126.7, 125.5, 105.9, 65.0, 13.8; IR (KBr) 3103, 2988, 2224, 1748, 1544.89,
36 928, 742 cm⁻¹; HRMS (ESI) m/z : [M+H]⁺ calcd for C₁₁H₁₀N₃O₇S 328.0239, found 328.0235.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

General Procedure for the Synthesis of Ester and Amide:

o-NosyLOXY (1 equiv) was added to a solution of acid (1 equiv) and DIPEA (1 equiv) in 2 ml of DCM. The reaction mixture was stirred for 3-5 min. for preactivation followed by the addition of alcohol or amine (1.0 equiv). The reaction mixture was stirred at room temperature for 2-3 h. After completion of the reaction, the reaction mixture was diluted with 50 ml of ethyl acetate; the organic phase was washed with 5% citric acid (3×20 ml), 5% NaHCO₃ (3×20 ml) and dried by anhydrous Na₂SO₄. Finally, Na₂SO₄ was filtered off and the solvent was evaporated to obtain the product which was purified by column chromatography.

General Procedure for the Synthesis of Dipeptides:

To a solution of *N*-protected amino acid (1 equiv) and *o*-NosyLOXY (1 equiv) in 2 ml of DCM, DIPEA (1.1 equiv) was added. The reaction mixture was stirred for 5 min. for preactivation followed by the addition of methyl ester of the second amino acid (1.1 equiv) and DIPEA (1.1 equiv) in 1 ml of DCM. The reaction mixture was stirred at room temperature for more 2-3 h. After completion of the reaction, the reaction mixture was diluted with 50 ml of ethyl acetate, the organic phase was washed with 5% citric acid (3×20 ml), 5% NaHCO₃ (3×20 ml), brine and dried over anhydrous Na₂SO₄. Finally, Na₂SO₄ was filtered and the solvent was evaporated. The product was purified by silica gel column chromatography.

General Procedure for the Synthesis of Hydroxamate:

To a solution of acid or *N*-protected amino acid (1 equiv) and *o*-NosyLOXY (1 equiv) in 2 ml of DCM, DIPEA (1.1 equiv) was added. The reaction mixture was stirred for 3-5 min. for preactivation followed by the addition of *O*-benzylhydroxylamine (1.1 equiv) and DIPEA (1.1 equiv) in 1 ml of DCM. The reaction mixture was stirred at room temperature (25 °C) for more

1
2
3 2-3 h. After completion of the reaction, the reaction mixture was diluted with 50 ml of ethyl
4 acetate, the organic phase was washed with 5% citric acid (3×20 ml), 5% NaHCO₃ (3×20 ml),
5
6 brine and dried over Na₂SO₄ anhydrous. Finally, Na₂SO₄ was filtered and the solvent was
7
8 evaporated. The product was purified by silica gel column chromatography.
9
10

11 12 13 **Solution Phase Synthesis of Boc-VVIA-OMe:** 14

15
16
17 Boc-isoleucine (750 mg, 3.24 mmol, 1 equiv,) and *o*-NosyLOXY (1059 mg, 3.24 mmol, 1
18 equiv) was taken in a 25 ml RB, after that DIPEA (0.85 ml, 4.86 mmol, 1.5 equiv) was added
19 and kept 5 min for pre-activation. In another oven dried 50 ml RB, methyl ester of alanine (675
20 mg, 4.86 mmol, 1.5 equiv) was taken in DCM and DIPEA was added to it until basic pH was
21 reached. Finally, this solution was added in first RB and stirring continued until completion of
22 the reaction. Then, the reaction mixture was diluted by 50 ml of EtOAc, washed by 5% NaHCO₃
23 solution (2 × 5 ml) and washed by 5% citric acid solution (2 × 5 ml). Finally, combined organic
24 layer was dried using anhydrous Na₂SO₄. Solid product (Boc-IA-OMe) was obtained after
25 evaporation of EtOAc by rotary vacuum evaporator.
26
27
28

29
30
31 In an oven dried 50 ml RB, Boc-IA-OMe was taken and 70% TFA solution in DCM was added
32 to it. Starring continued up to 2.5 h. After that, TFA was evaporated by rotary evaporator and
33 washed 3 times with diethyl ether and finally white solid (IA-OMe) was obtained.
34
35
36

37
38
39 After Boc deprotection, resulted IA-OMe was coupled with Boc-V-OH following the above
40 mentioned procedure to obtain Boc-VIA-OMe. Another cycle of Boc-deprotection and coupling
41 with Boc-V-OH, resulted white solid Boc-VVIA-OMe, which was characterized by reverse
42 phase HPLC, retention time was 12.8 minutes on linear gradient of 20 to 100% CH₃CN/0.09%
43 TFA in H₂O/0.09% TFA over 18 min, symmetry C8 analytical column and LRMS (ESI): m/z
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 [M+H]⁺ calculated for C₂₅H₄₇N₄O₇ is 537.3264 found 537.3421. Yield was 1298 mg, 78% with
4
5
6 respect to starting material Boc-isoleucine.
7

8 9 **Solid Phase Synthesis of NFGAILG-NH₂ and VQAAIDYING-NH₂:**

10
11
12 Specific amino acids were manually assembled on Fmoc-Rink Amide MBHA resin (loading
13
14 1.1 mmol/g) following Fmoc-^tBut orthogonal protection strategy. Fmoc-amino acids (3.2 equiv),
15
16 *o*-NosyLOXY (3 equiv) and DIPEA (5 equiv) was kept for pre-activation for 5 min. Amino acid
17
18 coupling was performed for 2 h. Fmoc deprotection was carried out with 25% piperidine/DMF (3
19
20 × 7 min). The peptide was cleaved from the resin using TFA/DCM/H₂O mixture for 2 h 30 min.
21
22 Purification of the peptide was performed using semi-preparative HPLC using a linear gradient
23
24 of 20 min (5 to 100 % ACN in water with 0.09% TFA) and characterized using ESI-MS.
25
26
27

28
29 For NFGAILG-NH₂, we took 300 mg of Fmoc-Rink Amide resin (loading 1.1 mmol/g), after
30
31 final coupling, peptide was cleaved from resin and purified by semi-preparative HPLC. The
32
33 purified yield of peptide was 90 mg, 40 %, HPLC profile and ESI-MS spectrum are shown in
34
35 supporting information (S153-154).
36
37

38
39 And for VQAAIDYING-NH₂, we took 300 mg of Fmoc-Rink Amide resin (loading 1.1
40
41 mmol/g), after final coupling, this peptide was also cleaved from resin and purified by semi-
42
43 preparative HPLC. Yield of the purified peptide was 175 mg, 50 %. HPLC profile and ESI-MS
44
45 spectrum are provided in supporting information (S167-168).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Intermediate V (Scheme 3): Oxyma ester naphthanoic acid

White solid; $R_f = 0.40$ (EtOAc:Hexane, 1.0:9.0), ^1H NMR (600 MHz, CDCl_3) δ 8.72 (s, 1H), 8.13-8.11 (t, $J = 8.0$ Hz, 1H), 8.00-7.98 (d, $J = 12.0$, Hz, 1H), 7.64-7.61 (t, $J = 12.0$ Hz, 2H), 7.64-7.61 (t, $J = 6.5$, Hz, 1H), 7.58-7.56 (t, $J = 6.6$, Hz, 1H), 4.46-4.43 (q, $J = 6.0$ Hz, 2H), 1.43-1.40 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 160.9, 157.1, 136.5, 133.1, 132.4, 129.9, 129.7, 129.2, 128.0, 127.4, 125.0, 122.8, 107.2, 64.7, 14.1; IR (KBr): 2924, 2853, 2224, 1715, 1646, 1593, 1541, 1398, 668, 544 cm^{-1} ; HRMS (ESI) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{12}\text{N}_2\text{NaO}_4$ 319.0695, found 319.0691. CCDC-936483 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Methyl 2-(2-(((9H-fluoren-9-yl)methoxy) carbonyl)amino)-3-phenylpropanamido)propanoate¹⁷ (by *o*-nitrobenzenesulfonyl chloride). Yield: 307 mg (65%); white solid; $R_f = 0.40$ (EtOAc:Hexane, 3.0:7.0); m.p.178-180 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.09-8.07 (m, 1H), 7.94-7.91 (m, 1H), 7.77-7.72 (m, 2H), 7.55-7.52 (t, $J = 12.0$ Hz, 2H), 7.42-7.38 (t, $J = 12.0$ Hz, 2H), 7.32-7.24 (m, 4H), 7.21-7.19 (m, 1H), 6.33 (br, 1H), 5.39 (br, 1H), 4.52-4.43 (m, 3H), 4.32-4.23 (m, 2H), 4.20-4.17 (t, $J = 8.0$ Hz, 1H), 3.52 (s, 3H), 3.12-3.05 (m, 1H), 1.50-1.48 (d, $J = 8.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 172.9, 172.1, 170.67, 156.08, 143.9, 141.4, 136.4, 133.7, 132.9, 130.6, 129.5, 128.5, 127.8, 127.8, 127.2, 125.7, 120.1, 67.2, 56.1, 52.2, 48.3, 47.2, 19.7, 18.3; IR (KBr): 3304, 1738, 1690, 1652, 1534, 1262, 698 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{29}\text{N}_2\text{O}_5$ 473.2076, found 473.2079.

(L) Methyl 2-(2-nitrophenylsulfonamido)propanoate (by *o*-nitrobenzenesulfonyl chloride)¹⁸: pale yellow solid; $R_f = 0.50$ (EtOAc:Hexane, 3.0:7.0); m.p.68-70 °C; ^1H NMR (400

1
2
3 MHz, CDCl₃): δ 8.29-8.27 (m, 1H), 8.07-8.05 (m, 1H), 7.92-7.90 (m, 1H), 7.74-7.71 (m, 1H),
4
5 6.18 (br, 1H), 4.23-4.19 (m, 1H), 3.50 (s, 3H), 1.50-1.48 (d, *J* = 8.0 Hz, 3H); ¹³C NMR (150
6
7 MHz, CDCl₃): δ 172.1, 147.9, 134.4, 133.8, 133.0, 130.6, 125.7, 52.7, 48.8, 16.7; IR (KBr):
8
9 3330, 2921, 1746, 1691, 1536, 1261, 1184, 741 cm⁻¹; HRMS (ESI): *m/z* [M+Na]⁺ calcd for
10
11 C₁₀H₁₂N₂NaO₆S 311.0314, found 311.0317.
12
13
14

15
16 ***N*-benzyl-2-nitrobenzenesulfonamide (byproduct of the reaction without pre-activation):**

17
18 pale yellow solid; *R_f* = 0.52 (EtOAc:Hexane, 3.0:7.0); ¹H NMR (400 MHz, CDCl₃): δ 8.01-7.98
19
20 (m, 1H), 7.83-7.81 (m, 1H), 7.70-7.63 (m, 2H), 7.31-7.22 (m, 5H), 5.77 (br, 1H), 4.33-4.32 (d, *J*
21
22 = 4.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 147.9, 135.8, 134.1, 133.6, 132.9, 131.1, 128.8,
23
24 128.0, 125.4, 48.0; IR (KBr): 3340, 2961, 1691, 1535, 1221, 1182, 933, 742 cm⁻¹; HRMS (ESI):
25
26 *m/z* [M+Na]⁺ calcd for C₁₃H₁₂N₂NaO₄S 315.0415, found 315.0420.
27
28
29
30

31 ***N*-benzylbenzamide (entry 1, Table 3).**¹⁹ Yield: 186 mg (88%); white solid; *R_f* = 0.50
32
33 (EtOAc:Hexane, 2.0:8.0) mp: 102-104 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.78-7.76 (m, 2H),
34
35 7.42-7.37 (m, 4H), 7.36-7.28 (m, 4H), 4.63-4.62 (d, *J* = 4.0 Hz, 2H); ¹³C NMR (100 MHz,
36
37 CDCl₃): δ 167.6, 138.4, 134.4, 131.6, 128.8, 128.6, 127.9, 127.5, 127.1, 44.1; IR (KBr): 3290,
38
39 2924, 1637, 1551, 765, 565 cm⁻¹; HRMS (ESI): *m/z* [M+H]⁺ calcd for C₁₄H₁₄NO 212.1075,
40
41 found 212.1073.
42
43
44
45

46 ***N*-benzyl-2-phenylacetamide (entry 2, Table 3).**¹⁹ Yield: 205 mg (91%); white solid; *R_f* = 0.51
47
48 (EtOAc:Hexane, 2.0:8.0); mp: 76-78 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.36-7.27 (m, 5H),
49
50 7.24-7.16 (m, 5H), 5.76 (br, 1H), 4.42 (s, 2H), 3.62 (s, 2H); ¹³C NMR (100 MHz, CDCl₃): δ
51
52 171.1, 138.3, 135.0, 129.4, 129.0, 128.7, 127.5, 127.4, 127.3, 43.7, 43.6; IR (KBr): 3289, 2925,
53
54
55
56
57
58
59
60

1
2
3 1638, 1552, 784, 634, 566 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{16}\text{NO}$ 226.1232, found
4 226.1231.
5
6
7

8
9 ***N*-(4-methoxyphenyl)-2-phenylacetamide (entry 3, Table 3).** Yield: 198 mg (82%); pale
10 yellowish solid; $R_f = 0.40$ (EtOAc:Hexane, 3.0:7.0); m.p.121-123°C; ^1H NMR (600 MHz,
11 CDCl_3): δ 7.39-7.37 (m, 2H), 7.35-7.29 (m, 5H), 7.12 (br, 1H), 6.81-6.79 (d, $J = 12.0$ Hz, 2H),
12 3.75 (s, 3H), 3.70 (s, 2H); ^{13}C NMR (150 MHz, CDCl_3): δ 169.3 156.7, 134.7, 130.8, 129.7,
13 129.3, 127.7, 122.0, 114.2, 55.6, 44.8; IR (KBr): 3330, 2930, 2832, 1751, 1519, 1262, 1188,
14 1016, 544 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{16}\text{NO}_2$ 242.1181, found 242.1183.
15
16
17
18
19
20
21
22
23

24 **2-*N*-Diphenyl-acetamide (entry 4, Table 3).**²⁰ Yield: 181 mg (86%); white solid; $R_f = 0.40$
25 (EtOAc:Hexane, 2.0:8.0); mp: 115-117 °C. ^1H NMR (400 MHz, CDCl_3): δ 7.42- 7.36 (m, 5H),
26 7.35-7.06 (m, 5H), 3.73 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 169.8, 137.9, 134.7, 129.5,
27 129.1, 128.9, 127.5, 124.5, 120.2, 44.6; IR (KBr): 3285, 2967, 1657, 1601, 865, 543 cm^{-1} ;
28 HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{14}\text{NO}$ 212.1075, found 212.1071.
29
30
31
32
33
34
35
36

37 **Benzyl 2-oxo-2-(piperidin-1-yl) ethylcarbamate (entry 5, Table 3).**²¹ Yield: 265 mg (89%);
38 white solid; $R_f = 0.30$ (EtOAc:Hexane, 4.0:6.0); mp: 113-116 °C; ^1H NMR (400 MHz, CDCl_3):
39 δ 7.32-7.28 (m, 5H), 5.84 (br, 1H), 5.09 (s, 2H), 3.98-3.97 (d, $J = 4.0$ Hz, 2H), 3.54-3.52 (t, $J =$
40 5.2 Hz, 2H), 3.29-3.27 (t, $J = 5.2$ Hz, 2H), 1.70-1.68 (d, $J = 4.0$ Hz, 2H), 1.63-1.61 (d, $J = 4.8$ Hz,
41 2H), 1.54-1.52 (d, $J = 5.6$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 166.0, 156.3, 136.6, 128.5,
42 128.1, 128.0, 66.8, 45.4, 43.1, 42.6, 34.0, 26.2, 25.7, 25.4, 25.0, 24.3; IR (KBr): 3293, 2936,
43 1707, 1641, 763, 541 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{NaO}_3$ 299.1372,
44 found 299.1368.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **(9H-fluoren-9-yl)methyl (1-(tert-butylamino)-1-oxopropan-2-yl) carbamate (entry 6, Table**
5
6 **3).** Yield: 296 mg (81%); yellowish solid; $R_f = 0.40$ (EtOAc:Hexane, 3.0:7.0); $[\alpha]_D^{25} = + 4.07$
7
8 (CHCl₃, $c = 0.54$); ¹H NMR (600 MHz, CDCl₃): δ 7.76-7.75 (d, $J = 12.0$ Hz, 2H), 7.59-7.57 (d, J
9
10 = 12.0 Hz, 2H), 7.41-7.38 (m, 2H), 7.32-7.29 (m, 2H), 4.43-4.37 (m, 3H), 4.24-4.19 (t, $J = 6.0$
11
12 Hz, 1H), 4.13 (br, 1H), 1.36-1.35 (d, $J = 6.0$ Hz, 3H), 1.34 (s, 9H); ¹³C NMR (150 MHz, CDCl₃):
13
14 δ 171.6, 156.1, 144.0, 141.5, 127.9, 127.2, 125.2, 120.1, 67.2 51.5, 47.3, 28.8, 19.1; IR (KBr):
15
16 3330, 3231, 2984, 1754, 1243, 752, 542 cm⁻¹; HRMS (ESI): m/z [M+H]⁺ calcd for C₂₂H₂₇N₂O₃
17
18 367.2022, found 367.2025.
19
20
21
22

23 **(L) Methyl 2-(2-(((9H-fluoren-9-yl)methoxy) carbonyl)amino) propanamido)-2-**
24 **methylpropanoate (entry 7, Table 3).** Yield: 328 mg (80%); white solid; $R_f = 0.50$
25
26 (EtOAc:Hexane, 3.0:7.0); ¹H NMR (400 MHz, CDCl₃): δ 7.77-7.75 (d, $J = 12.0$ Hz, 2H), 7.62-
27
28 7.58 (m, 2H), 7.42-7.38 (t, $J = 12.0$ Hz, 2H), 7.32-7.29 (t, $J = 12.0$ Hz, 2H), 5.42 (br, 1H), 4.43-
29
30 4.37 (m, 2H), 4.24-4.21 (t, $J = 8.0$ Hz, 1H), 4.16-4.10 (m, 1H), 3.76 (s, 3H), 1.44-1.42 (d, $J =$
31
32 12.0 Hz, 3H), 1.25 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 173.7, 155.8, 144.1, 141.5, 127.9,
33
34 127.2, 125.2, 124.9, 120.2, 76.9, 67.2, 52.7, 50.5, 49.8, 47.3, 29.7, 18.9; IR (KBr): 3341, 1722,
35
36 1654, 1650, 1231, 664 cm⁻¹; HRMS (ESI): m/z [M+H]⁺ calcd for C₂₃H₂₇N₂O₅ 411.1920, found
37
38 411.1922.
39
40
41
42
43
44

45 **Methyl 2-(2-(((9H-fluoren-9-yl) methoxy)carbonyl) acetamido)acetate (entry 8, Table 3).**

46
47 Yield: 321 mg (91%); white solid; $R_f = 0.31$ (EtOAc:Hexane, 4.0:6.0); mp: 162-163 °C; ¹H
48
49 NMR (400 MHz, CDCl₃): δ 7.76-7.74 (d, $J = 8.0$ Hz, 2H), 7.58-7.56 (d, $J = 8.0$ Hz, 2H), 7.40-
50
51 7.37 (t, $J = 8.0$ Hz, 2H), 7.31-7.27 (t, $J = 8.0$ Hz, 2H), 6.80 (br, 1H), 5.73 (br, 1H), 4.43-4.41 (d,
52
53 $J = 6.8$ Hz, 2H), 4.22-4.19 (t, $J = 7.2$ Hz, 1H), 4.04-4.03 (d, $J = 8.0$ Hz, 2H), 3.92-3.91 (d, $J =$
54
55 6.8 Hz, 2H), 3.73 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 169.9, 169.7, 156.8, 143.7, 141.2,
56
57 6.8 Hz, 2H), 3.73 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 169.9, 169.7, 156.8, 143.7, 141.2,
58
59
60

1
2
3
4
5
6
7
128.6, 128.5, 128.3, 127.1, 67.1, 47.0, 44.2, 41.2, 33.8; IR (KBr): 3316, 2931, 1734, 1692, 1654,
865, 523 cm^{-1} ; HRMS (ESI): m/z $[M+Na]^+$ calcd for $C_{20}H_{19}NNaO_5$ 376.1161, found 376.1165.

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
(L,L) Methyl 2-(2-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-methylpentanamido)propanoate (entry 9, Table 3) Yield: 390 mg (89%); white solid; $R_f = 0.50$ (EtOAc:Hexane, 3.0:7.0); mp: 161-163 $^{\circ}\text{C}$; $[\alpha]_D^{25} = -16.5$ (CHCl_3 , $c = 0.35$); ^1H NMR (400 MHz, CDCl_3): δ 7.76-7.74 (d, $J = 8.0$ Hz, 2H), 7.59-7.57 (d, $J = 8.0$ Hz, 2H), 7.41-7.37 (t, $J = 7.2$ Hz, 2H), 7.32-7.28 (t, $J = 7.2$ Hz, 2H), 6.62 (br, 1H), 5.36-5.34 (d, $J = 8.0$ Hz, 1H), 4.58-4.52 (m, 1H), 4.41-4.35 (m, 1H), 4.22-4.19 (t, $J = 6.4$ Hz, 3H), 3.73 (s, 3H), 1.81-1.74 (m, 1H), 1.65-1.63 (m, 2H), 1.40-1.38 (d, $J = 6.8$ Hz, 3H), 1.01-0.98 (d, $J = 6.5$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3): δ 174.2, 163.1, 156.6, 143.8, 141.1, 129.3, 128.6, 127.5, 126.9, 124.9, 66.6, 57.4, 52.2, 46.9, 38.2, 38.3, 28.1, 18.0; IR (KBr): 3307, 2925, 1754, 1694, 1654, 879, 534 cm^{-1} ; HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{25}H_{31}N_2O_5$ 439.2233, found 439.2235.

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(L,L) Methyl 2-(2-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-methylbutanamido)propanoate (entry 10, Table 3).²² Yield: 369 mg (87%); white solid; $R_f = 0.50$ (EtOAc:Hexane, 3.0:7.0); mp: 204-205 $^{\circ}\text{C}$; $[\alpha]_D^{25} = -14.5$ (CHCl_3 , $c = 0.40$); ^1H NMR (400 MHz, CDCl_3): δ 7.76-7.75 (d, $J = 8.0$ Hz, 2H), 7.60-7.58 (d, $J = 8.0$ Hz, 2H), 7.41-7.37 (t, $J = 8.0$ Hz, 2H), 7.31-7.28 (t, $J = 8.0$ Hz, 2H), 6.54-6.52 (d, $J = 8.0$ Hz, 1H), 5.54-5.52 (d, $J = 8.0$ Hz, 1H), 4.60-4.58 (d, $J = 8.0$ Hz, 2H), 4.44-4.35 (m, 1H), 4.23-4.21 (d, $J = 8.0$ Hz, 1H) 4.04-4.00 (t, $J = 7.0$ Hz, 1H), 3.73 (s, 3H), 2.11-2.08 (m, 1H), 1.41-1.39 (d, $J = 8.0$ Hz, 3H), 0.98-0.96 (d, $J = 8.0$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3): δ 173.3, 171.2, 156.6, 144.0, 141.4, 127.8, 127.2, 125.2, 120.1, 67.2, 60.4, 52.6, 48.2, 47.3, 31.9, 29.8, 19.2, 18.2; IR (KBr): 3296, 2953, 1745, 1692, 1650, 765, 599 cm^{-1} ; HRMS (ESI): m/z $[M+Na]^+$ calcd for $C_{24}H_{28}N_2NaO_5$ 447.1896, found 447.1901.

1
2
3
4 **(L) Methyl 2-(2-(((9H-fluoren-9-yl)methoxy)carbonyl)-3-phenylpropanamido)acetate**
5
6 **(entry 11, Table 3)** Yield: 412 mg (93%); white solid; $R_f = 0.52$ (EtOAc:Hexane, 3.0:7.0); mp:
7
8 175-178 °C; $[\alpha]_D^{25} = -6.5$ (CHCl₃, c = 0.60); ¹H NMR (400 MHz, CDCl₃): δ 7.77-7.75 (d, $J =$
9
10 8.0 Hz, 4H), 7.54-7.50 (t, $J = 8.0$ Hz, 2H), 7.42-7.38 (t, $J = 8.0$ Hz, 2H), 7.32-7.28 (m, 5H), 6.31
11
12 (br, 1H), 5.33 (br, 1H), 4.45-4.40 (t, $J = 8.0$ Hz, 2H), 4.40-4.32 (d, $J = 8.0$ Hz, 1H), 4.20-4.16 (t,
13
14 $J = 7.2$ Hz, 1H), 4.00-3.99 (d, $J = 4.0$ Hz, 2H) 3.72 (s, 3H); 3.10-3.00 (m, 2H); ¹³C NMR (150
15
16 MHz, CDCl₃): δ 171.5, 170.0, 156.2, 143.8, 141.4, 136.5, 129.4, 128.8, 128.5, 127.8, 127.7,
17
18 127.3, 127.2, 125.1, 120.1, 67.2, 56.1, 52.5, 47.2, 41.3, 38.5; IR (KBr): 3300, 1749, 1692, 1651,
19
20 1539, 1260, 757; HRMS (ESI): m/z [M+H]⁺ calcd for C₂₇H₂₆NO₅ 444.1811, found 444.1809.

21
22
23
24
25 **(L) Methyl 2-(2-(((9H-fluoren-9-yl)methoxy)carbonyl) propanamido)acetate (entry 12,**
26
27 **Table 3)** Yield: 319 mg (87%); white solid; $R_f = 0.40$ (EtOAc:Hexane, 4.0:6.0); mp: 157-
28
29 159 °C; $[\alpha]_D^{25} = -12.4$ (CHCl₃, c = 0.60); ¹H NMR (400 MHz, CDCl₃): δ 7.75-7.73 (d, $J = 8.0$
30
31 Hz, 2H), 7.56-7.55 (d, $J = 8.0$ Hz, 2H), 7.39-7.35 (t, $J = 8.0$ Hz, 2H), 7.30-7.27 (t, $J = 8.0$ Hz,
32
33 2H), 6.63 (br, 1H), 5.54 (br, 1H), 4.39-4.38 (t, $J = 4.0$ Hz, 2H), 4.31-4.30 (t, $J = 4.0$ Hz, 1H),
34
35 4.20-4.17 (d, $J = 4.0$ Hz, 1H), 4.01-3.99 (d, $J = 4.0$ Hz, 2H), 3.71 (s, 3H), 1.40-1.38 (d, $J = 8.0$
36
37 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃): δ 172.9, 170.2, 156.2, 143.9, 141.4, 127.8, 127.2, 125.2,
38
39 120.1, 67.2, 52.5, 50.5, 47.2, 41.3, 18.7; IR (KBr): 3294, 1731, 1693, 1648, 1551, 1265, 758 cm⁻¹;
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

(DL) Methyl 2-(2-(benzyloxycarbonyl)-3-phenyl propanamido)propanoate (entry 13, Table 3).²³ Yield: 345 mg (90%); white solid; $R_f = 0.51$ (EtOAc:Hexane, 3.0:7.0); mp: 120-122 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.35-7.30 (m, 4H), 7.29-7.26 (m, 4H), 7.23-7.17 (m, 2H), 6.60 (br, 1H), 5.53 (br, 1H), 5.05 (s, 2H), 4.53-4.51 (d, $J = 8.0$ Hz, 1H), 4.47-4.45 (d, $J = 8.0$ Hz, 1H), 3.67 (s, 3H), 3.07-3.05 (d, $J = 8.0$ Hz, 2H), 1.32-1.30 (d, $J = 8.0$ Hz, 3H), 1.21-1.19 (d, $J = 8.0$ Hz,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3H); ^{13}C NMR (100 MHz, CDCl_3): δ 173.0, 172.9, 170.9, 170.7, 156.1, 136.6, 136.3, 129.3, 128.4, 128.1, 127.9, 126.9, 66.9, 56.1, 52.4, 38.9, 38.6, 17.8 ppm; IR (KBr): 3305, 1737, 1690, 1652, 1537, 1262, 698 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{21}\text{H}_{24}\text{N}_2\text{NaO}_5$ 407.1583, found 407.1588.

(L) Methyl 2-(2-(benzyloxycarbonyl)-3-phenyl propanamido)propanoate (entry 14, Table 3).²³ Yield: 349 mg (91%); white solid; $R_f = 0.51$ (EtOAc:Hexane, 3.0:7.0); mp: 120-122 $^\circ\text{C}$. $[\alpha]_{\text{D}}^{25} = -12.1$ (CHCl_3 , $c = 0.32$); ^1H NMR (400 MHz, CDCl_3): δ 7.36-7.31 (m, 4H), 7.30-7.24 (m, 4H), 7.22-7.17 (m, 2H), 6.47 (br, 1H), 5.42 (br, 1H), 5.07 (s, 2H), 4.51-4.52 (d, $J = 4.0$ Hz, 1H), 4.48-4.46 (d, $J = 8.0$ Hz, 1H), 3.70 (s, 3H), 3.07-3.05 (d, $J = 8.0$ Hz, 2H), 1.32-1.31 (d, $J = 4.0$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3): δ 173.0, 170.7, 156.2, 136.4, 129.5, 128.8, 128.7, 128.6, 128.3, 128.2, 127.2, 67.2, 56.2, 52.6, 49.3, 48.12, 38.7, 18.4; IR (KBr): 3305, 1737, 1690, 1652, 1537, 1262, 698 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{21}\text{H}_{24}\text{N}_2\text{NaO}_5$ 407.1583, found 407.1587.

(L, L) Methyl 2-(2-(benzyloxycarbonyl)-4-(methylthio) butanamido)propanoate (entry 15, Table 3) Yield: 327 mg (89%); white solid; $R_f = 0.40$ (EtOAc:Hexane, 3.0:7.0); mp: 107-110 $^\circ\text{C}$. $[\alpha]_{\text{D}}^{25} = +6.8$ (CHCl_3 , $c = 0.70$); ^1H NMR (400 MHz, CDCl_3): δ 7.35-7.32 (m, 3H), 7.30-7.27 (m, 2H), 6.69 (br, 1H), 5.55 (br, 1H), 5.08 (s, 2H), 4.55-4.52 (t, $J = 8.0$ Hz, 1H), 4.39-4.37 (t, $J = 8.0$ Hz, 1H), 3.71 (s, 3H), 2.59-2.56 (t, $J = 8.0$ Hz, 2H), 2.08 (s, 3H), 2.00-1.94 (q, $J = 8.0$ Hz, 2H), 1.38-1.37 (d, $J = 4.0$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3): δ 173.1, 170.8, 156.1, 136.3, 128.7, 128.4, 128.3, 67.3, 54.0, 52.7, 48.3, 31.9, 30.0, 18.3, 15.4 ppm; IR (KBr): 3299, 1735, 1688, 1647, 1538, 1265, 697 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{N}_2\text{O}_5\text{S}$ 369.1484, found 369.1489.

1
2
3
4 **(L) Methyl 2-(2-(benzyloxycarbonyl)-2-methyl propanamido)propanoate (entry 16, Table**
5 **3).**²² Yield: 260 mg (81%); yellowish solid; $R_f = 0.50$ (EtOAc:Hexane, 2.0:8.0); mp: 67-70 °C;
6 $[\alpha]_D^{25} = -1.8$ (CHCl₃, $c = 0.70$); ¹H NMR (600 MHz, CDCl₃): δ 7.28-7.22 (m, 3H), 7.21-7.15 (m,
7 2H), 6.89 (br, 1H), 5.82-5.76 (t, $J = 8.0$ Hz, 1H), 4.98 (s, 2H), 4.43 (br, 1H), 3.58 (s, 3H), 1.32 (s,
8 6H), 1.17-1.14 (d, $J = 4.0$ Hz, 3H); ¹³C NMR (150 MHz, CDCl₃): δ 174.2, 173.5, 155.1, 136.4,
9 128.5, 128.1, 128.0, 66.6, 56.8, 52.4, 48.2, 25.1, 25.1, 18.0; IR (KBr): 3316, 1734, 1692, 1654,
10 1234, 674 cm⁻¹; HRMS (ESI): m/z [M+H]⁺ calcd for C₁₆H₂₃N₂O₅ 323.1607, found 323.1610.
11
12
13
14
15
16
17
18
19

20
21 **(L) Methyl 2-(2-(benzyloxycarbonyl)-2-methyl propanamido)-4-methylpentanoate (entry**
22 **17, Table 3).**²² Yield: 283 mg (78%); white solid; $R_f = 0.50$ (EtOAc:Hexane, 2.0:8.0); mp: 77-
23 80 °C; $[\alpha]_D^{25} = -1.5$ (CHCl₃, $c = 1.64$); ¹H NMR (600 MHz, CDCl₃): δ 7.35-7.32 (m, 3H), 7.31-
24 7.26 (m, 2H), 6.70 (br, 1H), 5.31 (br, 1H), 5.09 (s, 2H), 4.60-4.58 (t, $J = 4.0$ Hz, 1H), 3.71 (s,
25 3H), 1.65-1.61 (m, 3H), 1.50 (s, 3H), 1.49 (s, 3H), 0.95-0.92 (d, $J = 4.0$ Hz, 6H); ¹³C NMR (150
26 MHz, CDCl₃): δ 174.3, 173.6, 155.3, 136.4, 128.7, 128.6, 128.9, 66.9, 57.2, 52.39, 51.9, 41.6,
27 25.9, 25.2, 25.0, 22.9, 22.0; IR (KBr): 3346, 1723, 1653, 1653, 1235, 664 cm⁻¹; HRMS (ESI):
28 m/z [M+H]⁺ calcd for C₁₉H₂₉N₂O₅ 365.2076, found 365.2080.
29
30
31
32
33
34
35
36
37
38
39

40
41 **(L,L) 2-[2-(2-Benzyloxycarbonylamino-acetylamino)-3-phenyl-propionylamino]-3-methyl-**
42 **butyric acid methyl ester (entry 18, Table 3).**²³ Yield: 426 mg (91%); white solid; $R_f = 0.31$
43 (EtOAc:Hexane, 3.0:7.0); mp 101 °C; ¹H NMR (600 MHz, CDCl₃): δ 7.35-7.27 (m, 5H), 7.23-
44 7.11 (m, 5H), 5.88 (br, 1H), 5.11 (s, 2H), 4.78 (br, 1H), 4.43-4.40 (m, 2H), 3.88-3.84 (m, 2H),
45 3.60 (s, 3H), 3.04-2.99 (m, 2H), 2.06-2.03 (m, 1H), 0.87-0.84 (d, $J = 8.0$ Hz, 3H), 0.82-0.79 (d, J
46 = 8.0 Hz, 3H); ¹³C NMR (150 MHz, CDCl₃): δ 171.9, 171.4, 169.6, 156.7, 136.5, 136.4, 129.4,
47 129.0, 128.7, 128.6, 128.5, 128.1, 128.0, 126.8, 67.0, 57.5, 54.5, 52.0, 44.2, 38.5, 31.1, 18.8,
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

17.9; IR (KBr): 3406, 1728, 1677, 1651, 1646, 763, 543 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{32}\text{N}_3\text{O}_6$ 470.2291, found 470.2294.

***N*-(benzyloxy)benzamide (entry 1, Table.4).**²⁴ Yield: 208 mg (92%), yellowish solid; R_f = 0.50 (EtOAc:Hexane, 2.0:8.0); m.p.107-110 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 8.12-8.10 (m, 2H), 7.69-7.51 (m, 2H), 7.49-7.35 (m, 6H), 5.02 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 171.76, 133.75, 132.14, 130.27, 129.67, 129.43, 128.83, 128.70, 128.67, 128.55, 127.34, 78.46; IR (KBr): 2963, 1626, 1522, 1145, 1001, 747, 638 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{14}\text{NO}_2$ 228.1025, found 228.1023.

***N*-(benzyloxy)-2-naphthamide (entry 2, Table.4).**Yield: 249 mg (90%); white solid; R_f = 0.50 (EtOAc:Hexane, 2.0:8.0); m.p 126-129 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 9.01 (s, br), 8.16 (s, 1H), 7.82-7.79 (d, J = 12.0 Hz, 2H), 7.70-7.68 (m, 1H), 7.53-7.46 (m, 2H), 7.43-7.42 (m, 3H), 7.38-7.34 (m, 3H), 5.04 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 166.7, 135.2, 135.0, 132.8, 129.6, 129.3, 129.1, 128.9, 128.2, 128.0, 127.1, 123.56, 78.4; IR (KBr): 3208, 2920, 1647, 1501, 1123, 908, 752, 699, 533, 505 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{16}\text{NO}_2$ 278.1181, found 278.1185.

***N*-(benzyloxy)-3-(1H-indol-3-yl)propanamide (entry 3, Table.4).**²⁵ Yield: 261 mg (89%), white solid; R_f = 0.50 (EtOAc:Hexane, 2.0:8.0); m.p. 145-147 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 7.57-7.55 (d, J = 8.0 Hz, 1H), 7.37-7.35 (d, J = 8.0 Hz, 1H), 7.27-7.34 (m, 3H), 7.18-7.16 (m, 3H), 7.09-7.05 (m, 1H), 6.98 (s, 1H), 4.70 (s, 2H), 3.10-3.06 (t, J = 8.0 Hz, 2H), 2.42-2.38 (t, J = 8.0 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ 171.02, 136.36, 135.06, 129.00, 128.28, 128.11, 128.11, 126.84, 122.01, 121.26, 118.50, 118.13, 113.28, 111.15, 76.91, 33.67, 20.95; IR (KBr):

3402, 2922, 1656, 1502, 1145, 1001, 743, 698, 616, 516 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_2$ 295.1447, found 295.1443.

(9H-fluoren-9-yl)methyl 2-(benzyloxyamino)-2-oxoethyl carbamate (entry 4, Table.4) Yield:

366 mg (91%); white solid; R_f = 0.40 (EtOAc:Hexane, 4.0:6.0); m.p 114-118 $^{\circ}\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 9.34 (br, 1H), 7.76-7.73 (d, J = 12.0 Hz, 2H), 7.41-7.38 (m, 2H), 7.36-7.27 (m, 4H), 7.15-7.11 (m, 5H), 5.58 (br, 1H), 4.85 (s, 2H), 4.26-4.24 (d, J = 8.0 Hz, 2H), 4.07-4.06 (d, J = 4.0 Hz, 2H), 3.70-3.68 (d, J = 8.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 167.1, 156.9, 143.8, 141.4, 129.4, 128.9, 128.7, 127.9, 127.2, 125.2, 120.1, 78.5, 67.5, 47.2, 42.6; IR (KBr): 3334, 2912, 1702, 1674, 1540, 1272, 1167, 756, 698, 534 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{23}\text{N}_2\text{O}_4$ 403.1658, found 403.1654.

(9H-fluoren-9-yl)methyl 1-(benzyloxyamino)-1-oxopropan-2-ylcarbamate (entry 5,

Table.4).²⁶ Yield: 366 mg (88%); white solid; R_f = 0.50 (EtOAc:Hexane, 4.0:6.0); m.p 142-144 $^{\circ}\text{C}$; $[\alpha]_{\text{D}}^{25}$ = - 13.4 (CHCl_3 , c = 0.10); ^1H NMR (400 MHz, CDCl_3): δ 9.27 (br, 1H), 7.75-7.73 (d, J = 8.0 Hz, 2H), 7.54-7.53 (d, J = 4.0 Hz, 2H), 7.38-7.32 (m, 4H), 7.31-7.25 (m, 5H), 5.51 (br, 1H), 4.86 (s, 2H, 2H), 4.30 (d, J = 4.0 Hz, 2H), 4.14-4.12 (m, 2H), 1.25 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3): δ 169.9, 156.2, 143.7, 141.4, 135.1, 129.3, 128.9, 128.7, 127.9, 127.2, 125.2, 120.1, 78.3, 67.3, 48.2, 47.1, 18.0; IR (KBr): 3294, 2923, 1690, 1664, 1537, 1260, 755, 739, 521 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{25}\text{N}_2\text{O}_4$ 417.1814, found 417.1811.

(9H-fluoren-9-yl)methyl 1-(benzyloxyamino)-4-methyl-1-oxopentan-2-ylcarbamate (entry 6,

Table.4) Yield: 385 mg (84%); white solid; R_f = 0.50 (EtOAc:Hexane, 3.0:7.0); m.p 157-160 $^{\circ}\text{C}$; $[\alpha]_{\text{D}}^{25}$ = - 12.4 (CHCl_3 , c = 0.41); ^1H NMR (400 MHz, CDCl_3): δ 9.59 (br, 1H), 7.73-7.71 (d, J = 8.0 Hz, 2H), 7.57-7.49 (m, 4H), 7.35-7.25 (m, 7H), 5.59 (d, J = 8.0 Hz, 1H), 4.85 (s, 2H), 4.29-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4.27 (d, $J = 8.0$ Hz, 2H), 4.23-4.20 (t, $J = 8.0$ Hz, 1H), 4.14-4.12 (t, $J = 8.0$ Hz, 1H), 1.57-1.54 (m, 2H), 0.92-0.91 (d, $J = 4.0$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3): δ 169.8, 156.4, 143.7, 141.3, 135.1, 129.3, 128.7, 128.5, 127.4, 127.1, 125.1, 120.0, 78.2, 67.3, 50.9, 47.0, 41.3, 24.7, 22.6, 22.4; IR (KBr): 3311, 2957, 1688, 1666, 1535, 1248, 1040, 765, 532, 458 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{31}\text{N}_2\text{O}_4$ 459.2284, found 459.2279.

(9H-fluoren-9-yl)methyl 1-(benzyloxyamino)-3-methyl-1-oxobutan-2-ylcarbamate (entry 7, Table 4) Yield: 364 mg (82%); white solid; $R_f = 0.40$ (EtOAc:Hexane, 3.0:7.0); m.p 205-208 $^\circ\text{C}$; $[\alpha]_{\text{D}}^{25} = -18.7$ (CHCl_3 , $c = 0.50$); ^1H NMR (400 MHz, CDCl_3): δ 9.54 (br, 1H), 7.73-7.71 (d, $J = 8.0$ Hz, 2H), 7.53-7.51 (m, 2H), 7.36-7.35 (m, 3H), 7.27-7.24 (m, 6H), 5.72-5.70 (d, $J = 8.0$ Hz, 1H), 4.84 (s, 2H), 4.30-4.28 (d, $J = 8.0$ Hz, 2H), 4.22-4.19 (d, $J = 4.0$ Hz, 1H), 2.04-2.01 (m, 1H), 0.91 (d, $J = 4.0$ Hz, 6H); ^{13}C NMR (150 MHz, CDCl_3): δ 169.0, 156.7, 143.8, 141.4, 135.1, 129.4, 128.9, 128.6, 127.3, 127.2, 125.3, 120.1, 78.5, 67.4, 58.3, 47.2, 31.1, 19.2, 18.5; IR (KBr): 3281, 2961, 1698, 1657, 1544, 1294, 1251, 748, 742, 541 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{29}\text{N}_2\text{O}_4$ 445.2127, found 445.2131.

(9H-fluoren-9-yl)methyl 1-(benzyloxyamino)-4-(methylthio)-1-oxobutan-2-ylcarbamate (entry 8, Table 4) Yield: 385 mg (81%); white solid; $R_f = 0.50$ (EtOAc:Hexane, 3.0:7.0); m.p 171-174 $^\circ\text{C}$; $[\alpha]_{\text{D}}^{25} = -15.3$ (CHCl_3 , $c = 0.37$); ^1H NMR (600 MHz, CDCl_3): δ 9.05 (br, 1H), 7.76-7.74 (d, $J = 8.0$ Hz, 2H), 7.54-7.51 (m, 2H), 7.37-7.35 (m, 3H), 7.28-7.25 (m, 6H), 5.52 (br, 1H), 4.89 (s, 2H), 4.30-4.28 (d, $J = 8.0$ Hz, 2H), 4.22-4.19 (m, 2H), 2.59-2.56 (q, $J = 4.0$ Hz, 2H), 2.09 (s, 3H), 2.04-2.01 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 168.9, 156.4, 143.7, 141.4, 135.1, 129.4, 128.9, 128.6, 127.3, 127.2, 125.3, 120.1, 78.5, 67.4, 51.3, 47.2, 31.6, 30.0, 15.5; IR (KBr): 3281, 2961, 1698, 1657, 1544, 1294, 1251, 748, 742, 541 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{29}\text{N}_2\text{O}_4\text{S}$ 477.1848, found 477.1852.

1
2
3 **Phenyl 2-phenylacetate (entry 1, Table 6).**²⁷ Yield: 184 mg (87%); yellowish oil; $R_f = 0.51$
4 (EtOAc:Hexane, 1.0:9.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.38-7.30 (m, 7H), 7.22-7.18 (m, 1H),
5 7.05-7.04 (m, 2H), 3.85 (s, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 170.4, 151.2, 134.0, 129.8,
6 129.7, 129.1, 127.7, 126.2, 121.8, 41.7; IR (KBr): 2924, 2853, 1759, 1593, 1398, 1261, 1088,
7 1016, 696; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{13}\text{O}_2$ 213.091, found 213.0911.
8
9
10
11
12
13
14
15

16 **4-Methoxyphenyl 2-phenylacetate (entry 2, Table 6)** Yield: 198 mg (82%); clear oil; $R_f = 0.50$
17 (EtOAc:Hexane, 1.0:9.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.37-7.35 (m, 5H), 6.97-6.95 (d, $J =$
18 8.0 Hz, 2H), 6.86-6.84 (d, $J = 8.0$ Hz, 2H), 3.83 (s, 2H), 3.76 (s, 3H); $^{13}\text{C NMR}$ (150 MHz,
19 CDCl_3): δ 170.9, 157.48, 144.6, 133.7, 129.5, 128.9, 127.5, 122.4, 114.6, 55.7, 41.5 ppm; IR
20 (KBr): 2930, 2837, 1754, 1509, 1267, 1188, 1016, 544 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd
21 for $\text{C}_{15}\text{H}_{14}\text{NaO}_3$ 265.0835, found 265.0832.
22
23
24
25
26
27
28
29
30

31 **4-Nitrophenyl 2-phenylacetate (entry 3, Table 6)** Yield: 231 mg (90%); clear oil; $R_f = 0.50$
32 (EtOAc/Hexane, 1.0:9.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.26-8.23 (d, $J = 12.0$ Hz, 2H), 7.39-
33 7.37 (m, 5H), 7.26-7.24 (d, $J = 8.0$ Hz, 2H), 3.90 (s, 2H); $^{13}\text{C NMR}$ (150 MHz, CDCl_3): δ 169.3,
34 155.6, 145.5, 130.5, 129.5, 128.8, 127.9, 125.5, 122.5, 41.5; IR (KBr): 2924, 2851, 1764, 1593,
35 1524, 1347, 1216, 1114 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{14}\text{H}_{11}\text{NNaO}_4$ 280.0586,
36 found 280.0583.
37
38
39
40
41
42
43
44
45

46 **Pentafluorophenyl 2-phenylacetate (entry 4, Table 6)**²⁸ Yield: 245 mg (81%); clear oil; $R_f =$
47 0.51 (EtOAc:Hexane, 1.0:9.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.40-7.38 (m, 2H), 7.36-7.32 (m,
48 3H), 3.96 (s, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 167.7, 132.3, 129.4, 129.2, 129.0, 128.8,
49 128.0, 127.7, 40.1; IR (KBr): 3055, 2929, 1776, 1740, 1456, 1220, 1094, 1003, 732, 696, 557
50 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{14}\text{H}_7\text{F}_5\text{NaO}_2$ 325.0258, found 325.0256.
51
52
53
54
55
56
57
58
59
60

1
2
3 **Benzyl 2-phenylacetate (entry 5, Table 6).**²⁹ Yield: 229 mg (92%), colorless oil; $R_f = 0.60$
4 (EtOAc:Hexane, 1.0:9.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.35-7.31 (m, 5H), 7.28-7.26 (m, 5H),
5 5.13 (s, 2H), 3.67 (s, 2H); $^{13}\text{C NMR}$ (150 MHz, CDCl_3): δ 171.4, 135.9, 134.0, 129.3, 128.6,
6 128.6, 128.2, 128.1, 127.2, 66.6, 41.3; IR (KBr): 3032, 1737, 1497, 1455, 1259, 1146, 725, 491
7 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{15}\text{H}_{14}\text{NaO}_2$ 249.0886, found 249.0889.
8
9

10
11
12
13
14
15
16 **Tert-butyl 2-phenylacetate (entry 6, Table 6).**³⁰ Yield: 161 mg (84%); clear oil; $R_f = 0.50$
17 (EtOAc:Hexane, 1.0:9.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.32-7.22 (m, 5H), 3.51 (s, 2H), 1.45
18 (s, 9H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 170.9, 134.7, 129.2, 128.5, 126.8, 80.7, 42.6, 28.0; IR
19 (KBr): 3230, 2989, 1754, 1243, 752, 543 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{12}\text{H}_{16}\text{NaO}_2$
20 215.1048, found 215.1051.
21
22
23
24
25
26
27

28
29 **Isopropyl 2-phenylacetate (entry 7, Table 6).** Yield: 158 mg (89%); clear oil; $R_f = 0.51$
30 (EtOAc:Hexane, 1.0:9.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.33-7.29 (m, 3H), 7.28-7.26 (m, 2H),
31 5.03-4.97 (m, 1H), 3.57 (s, 2H), 1.22 (s, 3H), 1.20 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 171.2,
32 134.4, 129.3, 128.6, 127.0, 68.2, 41.8, 21.8; IR (KBr): 2934, 2827, 1754, 1522, 1436, 1266, 1126,
33 563 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{11}\text{H}_{14}\text{NaO}_2$ 201.0891, found 201.0894.
34
35
36
37
38
39
40

41
42 **Benzyl benzoate (entry 8, Table 6).**²⁷ Yield: 180 mg (85%); colorless oil; $R_f = 0.50$
43 (EtOAc:Hexane, 2.0:8.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.09-8.06 (d, $J = 12\text{Hz}$, 2H), 7.57-7.53
44 (t, 1H), 7.45-7.42 (m, 3H), 7.40-7.33 (m, 4H), 5.39 (s, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ
45 166.5, 136.2, 133.1, 130.3, 129.8, 128.7, 128.5, 128.4, 128.3, 66.8; IR (KBr): 2853, 1749, 1543,
46 1352, 1273, 1043, 654, 544 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{14}\text{H}_{12}\text{NaO}_2$ 235.0735,
47 found 235.0738.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Benzyl butyrate (entry 9, Table 6)**³¹ Yield: 162 mg (91%); oily; $R_f = 0.50$ (EtOAc:Hexane,
4 0.5:9.5); ^1H NMR (400 MHz, CDCl_3): δ 7.36-7.34 (m, 1H), 7.31-7.30 (m, 4H), 5.10 (s, 2H),
5 2.34-2.31 (t, $J = 8.0$ Hz, 2H), 1.69-1.64 (q, 2H), 0.95-0.92 (t, $J = 8.0$ Hz, 3H); ^{13}C NMR (100
6 MHz, CDCl_3): δ 173.5, 136.3, 128.6, 128.2, 66.1, 36.2, 18.5, 13.7; IR (KBr): 2928, 1738, 1754,
7 1381, 1253, 1171, 697 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{11}\text{H}_{14}\text{NaO}_2$ 201.0891, found
8 201.0889.
9
10
11
12
13
14
15
16

17
18 **Naphthalen-2-yl 4-nitrobenzoate (entry 10, Table 6)** Yield: 263 mg (90%); white solid; $R_f =$
19 0.51 (EtOAc:Hexane, 1.0:9.0); m.p.167-170 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 9.07 (s, 1H),
20 8.65-8.54 (d, $J = 8.0$ Hz, 1H), 8.50-8.48 (d, $J = 8.0$ Hz, 1H), 7.92-7.84 (m, 3H), 7.75-7.70 (m,
21 2H), 7.52-7.49 (m, 2H) 7.37-7.34 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 163.6, 151.0, 148.3,
22 135.1, 133.9, 131.8, 131.4, 129.9, 128.0, 127.9, 127.8, 127.0, 126.8, 126.2, 126.0, 123.9, 120.8,
23 118.7; IR (KBr): 2922, 2852, 1724, 1593, 1424, 1347, 1299, 1096 cm^{-1} ; HRMS (ESI): m/z
24 $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{11}\text{NNaO}_4$ 316.0586, found 316.0583.
25
26
27
28
29
30
31
32
33
34
35

36 **(9H-fluoren-9-yl)methyl 4-bromobenzoate (entry 11, Table 6).**³² Yield: 336 mg (89%); white
37 crystalline solid; $R_f = 0.50$ (EtOAc:Hexane, 1.0:9.0); m.p.98-102 $^\circ\text{C}$; ^1H NMR (400 MHz,
38 CDCl_3): δ 7.91-7.89 (d, $J = 8.0$ Hz, 2H), 7.78-7.76 (d, $J = 8.0$ Hz, 2H), 7.61-7.59 (m, 4H), 7.42-
39 7.48 (t, $J = 8.0$ Hz, 2H), 7.32-7.28 (t, $J = 8.0$ Hz, 2H), 4.61-4.59 (d, $J = 8.0$ Hz, 2H), 4.37-4.35 (t,
40 $J = 8.0$ Hz, 1H); ^{13}C NMR (150 MHz, CDCl_3): δ 165.9, 143.8, 141.5, 132.1, 131.3, 129.2, 128.4,
41 128.0, 127.3, 125.1, 120.3, 67.4, 47.1; IR (KBr): 3030, 2890, 1727, 1590, 1452, 1241, 1118,
42 1010, 751, 551 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{21}\text{H}_{15}\text{BrNaO}_2$ 401.0153, found
43 401.0157.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Butyl cinnamate (entry 12, Table 6)** Yield: 186 mg (91%); clear oil; $R_f = 0.50$ (EtOAc:Hexane,
5 1.0:9.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.86-7.64 (d, $J = 12.0$ Hz, 1H), 7.51-7.49 (m, 2H), 7.37-
6 7.35 (m, 3H), 6.44-6.40 (d, $J = 12.0$ Hz, 1H), 4.20-4.17 (t, $J = 8.0$ Hz, 2H), 1.70-1.63 (m, 2H),
7 1.44-1.39 (m, 2H), 0.96-0.92 (t, $J = 8.0$ Hz, 3H); $^{13}\text{C NMR}$ (150 MHz, CDCl_3): δ 167.2, 144.6,
8 134.6, 130.3, 129.0, 128.1, 118.47, 64.5, 30.9, 19.3, 13.8; IR (KBr): 2960, 2873, 1714, 1638,
9 1450, 1311, 1172, 980, 767, 684, 486 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{13}\text{H}_{16}\text{NaO}_2$
10 227.1048, found 227.1045.
11
12
13
14
15
16
17
18
19

20
21 **Butyl 2-naphthoate (entry 13, Table 6)** Yield: 198 mg (87%); oily; $R_f = 0.51$ (EtOAc:Hexane,
22 1.0:8.0); $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.60 (s, 1H), 8.08-8.06 (d, $J = 8.0$ Hz, 2H), 8.93-8.91 (d,
23 $J = 8.0$ Hz, 2H), 7.84-7.81 (m, 2H), 4.39-4.36 (t, $J = 4.0$ Hz, 2H), 1.82-1.75 (q, 2H), 1.53-1.47 (q,
24 $J = 8.0$ Hz, 2H), 7.84-7.81 (m, 2H), 4.39-4.36 (t, $J = 4.0$ Hz, 2H), 1.82-1.75 (q, 2H), 1.53-1.47 (q,
25 2H), 1.01-0.98 (t, $J = 8.0$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 166.6, 135.5, 132.5, 130.9,
26 129.3, 128.2, 127.8, 126.6, 125.3, 65.0, 30.9, 19.4, 13.8; IR (KBr): 2959, 2873, 1716, 1632, 1466,
27 1286, 1196, 955, 779, 474 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{15}\text{H}_{16}\text{NaO}_2$ 251.1048,
28 found 251.1051.
29
30
31
32
33
34
35
36
37

38
39 **4-Methoxyphenyl palmitate (entry 1, Table 7).**³³ Yield: 311 mg (86%); white solid powder; R_f
40 = 0.50 (EtOAc:Hexane, 0.5:9.5); m.p. 52-52 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 6.98-6.95 (d, $J =$
41 12.0 Hz, 2H), 6.87-6.85 (d, $J = 8.0$ Hz, 2H), 3.77 (s, 3H), 2.52-2.48 (t, $J = 8.0$ Hz, 2H), 1.72-1.70
42 (m, 2H), 1.26-1.21 (m, 24H), 0.87-0.84 (t, $J = 8.0$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ
43 172.8, 157.3, 144.5, 122.4, 114.5, 55.6, 34.5, 32.1, 29.8, 29.7, 29.6, 29.5, 29.4, 29.2, 25.1, 22.9
44 14.3; IR (KBr): 2916, 2849, 1746, 1552, 1509, 1463, 1213, 1033, 844 cm^{-1} ; HRMS (ESI): m/z
45 $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{23}\text{H}_{38}\text{NaO}_3$ 385.2719, found 385.2716.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **4-Nitrobenzyl tetradecanoate (entry 2, Table 7)** Yield: 308 mg (92%); oily $R_f = 0.51$
5 (EtOAc:Hexane, 0.5:9.5); ^1H NMR (400 MHz, CDCl_3): δ 8.20-8.18 (d, $J = 8.0$ Hz, 2H), 7.49-
6 7.47 (d, $J = 8.0$ Hz, 2H), 5.17 (s, 2H), 2.38 (t, $J = 8.0$ Hz, 2H), 1.64-1.60 (m, 2H), 1.26-1.21 (m,
7 16H), 0.85-0.82 (t, $J = 8.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 173.4, 147.7, 143.6, 128.4,
8 123.8, 64.6, 34.3, 32.0, 29.7, 29.5, 29.4, 29.3, 29.2, 25.0, 22.8, 14.2; IR (KBr): 2926, 2853, 1743,
9 1607, 1524, 1347, 1015, 859, 738 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{30}\text{NO}_4$
10 336.2175 found 336.2171.
11
12
13
14
15
16
17
18
19

20
21 **Naphthalen-2-yl octanoate (entry 3, Table 7)** Yield: 246 mg (91%); white solid; $R_f = 0.50$
22 (EtOAc:Hexane, 1.0:9.0); m.p.42-43 $^\circ\text{C}$; ^1H NMR (400 MHz, CDCl_3): δ 7.83-7.81 (m, 2H),
23 7.78-7.76 (d, $J = 8.0$ Hz, 1H), 7.53 (s, 1H), 7.46-7.43 (m, 2H), 7.22-7.19 (m, 1H), 2.61-2.57 (t, J
24 = 8.0 Hz, 2H), 1.81-1.74 (m, 2H), 1.43-1.31 (m, 10H), 0.91-0.88 (t, $J = 8.0$ Hz, 3H); ^{13}C NMR
25 (150 MHz, CDCl_3): δ 172.6, 148.6, 134.0, 131.6, 129.5, 127.9, 127.8, 126.7, 125.8, 121.4, 118.7,
26 34.6, 31.8, 29.3, 29.1, 25.2, 22.8, 14.2; IR (KBr): 2928, 2852, 1751, 1510, 1211, 1162, 812, 634,
27 483 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{22}\text{NaO}_2$ 293.1517, found 293.1521.
28
29
30
31
32
33
34
35
36
37

38 **4-nitrophenyl 2-hydroxybenzoate (entry 4, Table 7).**³⁴ Yield: 224 mg (82%); colourless solid;
39 $R_f = 0.50$ (EtOAc:Hexane, 1.0:9.0); ^1H NMR (400 MHz, CDCl_3): δ 10.53 (s, 1H), 8.25-8.23 (d, J
40 = 8.0 Hz, 2H) 7.88-7.86 (d, $J = 8.0$ Hz, 1H), 7.60-7.58 (d, $J = 8.0$ Hz, 2H), 7.49-7.45 (t, $J = 8.0$
41 Hz, 1H), 6.99-6.97 (d, $J = 8.0$ Hz, 1H), 6.91-6.87 (t $J = 8.0$ Hz, 1H), 5.22 (s, 2H); ^{13}C NMR (100
42 MHz, CDCl_3): δ 169.7, 162.0, 148.0, 142.6, 136.4, 129.9, 128.6, 124.0, 119.5, 117.9, 112.0,
43 65.5; IR (KBr): 3427, 2967, 2851, 1725, 1524, 1339, 1253, 754, 532 cm^{-1} ; HRMS (ESI): m/z
44 $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{14}\text{H}_{10}\text{NO}_5$ 272.0559, found 272.0557.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Hexadecyl 3-(1H-indol-3-yl)propanoate (entry 5, Table 7).**³⁵ Yield: 355 mg (86%); yellowish
5
6 crystalline solid; $R_f = 0.50$ (EtOAc:Hexane, 2.0:8.0); m.p. 60-62 °C; ^1H NMR (400 MHz,
7
8 CDCl_3): δ 7.97 (br, 1H), 7.60-7.58 (d, $J = 8.0$ Hz, 1H), 7.34-7.32 (d, $J = 8.0$ Hz, 1H), 7.20-7.16 (t,
9
10 $J = 8.0$ Hz, 1H), 7.13-7.09 (t, $J = 8.0$ Hz, H), 6.98 (s, 1H), 4.07-4.04 (t, 2H), 3.11-3.07 (t, $J = 8.0$
11
12 Hz, 2H), 2.72-2.68 (t, $J = 8.0$ Hz, 2H), 1.59-1.57 (m, 2H), 1.26-1.23 (m, 26H), 0.90-0.85 (t, $J =$
13
14 8.0 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 173.8, 136.5, 127.3, 122.1, 121.6, 119.4, 118.8,
15
16 115.0, 111.3, 64.8, 35.2, 32.1, 29.8, 29.7, 29.5, 29.4, 28.8, 26.1, 25.8, 22.8, 20.8, 14.3; IR (KBr):
17
18 3342, 2916, 2848, 1718, 1471, 1279, 1186, 734, 552 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for
19
20 $\text{C}_{27}\text{H}_{44}\text{NO}_2$ 414.3372, found 414.3368.
21
22
23
24

25
26 **Ethyl 3-(indolin-3-yl)propanoate (entry 6, Table 7).**³⁶ Yield: 195 mg (90%); yellowish solid;
27
28 $R_f = 0.50$ (EtOAc:Hexane, 2.0:8.0); m.p. 39-41 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.05 (br, 1H),
29
30 7.60-7.58 (d, $J = 8.0$ Hz, 1H), 7.30-7.28 (d, $J = 8.0$ Hz, 1H), 7.19-7.15 (t, $J = 8.0$ Hz, 1H), 7.12-
31
32 7.08 (t, $J = 8.0$ Hz, H), 6.97 (s, 1H), 4.15-4.07 (q, 2H), 3.11-3.07 (t, $J = 8\text{Hz}$, 2H), 2.72-2.68 (t, J
33
34 = 8.0 Hz, 2H), 1.23-1.19 (t, $J = 8.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 173.8, 136.4, 127.2,
35
36 122.0, 121.7, 119.2, 118.7, 114.6, 111.3, 60.5, 35.1, 20.7, 14.2; IR (KBr): 3345, 2926, 2841,
37
38 1728, 1472, 1272, 1183, 724, 562 cm^{-1} ; HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{16}\text{NO}_2$
39
40 218.1181, found 218.1177.
41
42
43
44

45
46 **(1S, 2R, 5S)-2-isopropyl-5-methylcyclohexyl nicotinate (entry 7, Table 7).**³⁵ Yield: 235 mg
47
48 (90%); oily $R_f = 0.50$ (EtOAc:Hexane, 1.0:9.0); ^1H NMR (400 MHz, CDCl_3): δ 9.18 (s, 1H,
49
50 $1 \times \text{ArH}$), 8.73-8.71 (d, $J = 8.0$ Hz, 1H), 8.26-8.24 (d, $J = 8.0$ Hz, 1H), 7.36-7.33 (t, $J = 8.0$ Hz,
51
52 1H), 4.96-4.89 (s, 1H), 2.10-2.05 (m, 1H), 1.91-1.87 (m, 1H), 1.72-1.67 (m, 2H), 1.56-1.49 (m,
53
54 2H), 1.12-1.06 (m, 2H), 0.93-0.88 (m, 6H), 0.76-0.74 (d, $J = 8.0$ Hz, 3H); ^{13}C NMR (150 MHz,
55
56 CDCl_3): δ 164.9, 153.3, 151.0, 137.2, 126.8, 123.4, 75.7, 47.3, 41.0, 34.4, 31.6, 26.7, 23.8, 22.1,
57
58
59
60

20.9, 16.6 ppm; IR (KBr): 2957, 2870, 1719, 1591, 1289, 1121, 741 cm^{-1} ; HRMS (ESI): m/z [M+H]⁺ calcd for $\text{C}_{16}\text{H}_{24}\text{NO}_2$ 262.1807, found 262.1810.

2-Octyldodecyl benzoate (entry 8, Table 7). Yield: 358 mg (89%); oily $R_f = 0.50$ (EtOAc:Hexane, 0.5:9.5); ¹H NMR (400 MHz, CDCl_3): δ 8.03-8.01 (d, $J = 8.0$ Hz, 2H), 7.55-7.53 (m, 1H), 7.42-7.40 (m, 2H), 4.21-4.17 (m, 1H), 1.76-1.74 (m, 1H), 1.29-1.23 (m, 32H), 0.86-0.83 (m, 6H); ¹³C NMR (150 MHz, CDCl_3): δ 166.8, 132.8, 130.7, 129.8, 129.4, 128.4, 128.1, 67.8, 37.6, 37.3, 32.1, 31.8, 31.6, 31.3, 31.1, 30.1, 29.8, 29.7, 29.5, 27.0, 26.8, 26.6, 22.8, 22.6, 14.3, 14.0; IR (KBr): 2925, 2854, 1723, 1466, 1272, 1133, 710 cm^{-1} ; HRMS (ESI): m/z [M+H]⁺ calcd for $\text{C}_{27}\text{H}_{46}\text{NaO}_2$ 425.3319, found 425.3314.

Methyl 2-(((9H-fluoren-9-yl)methoxy)carbonyl) propanoate (entry 9, Table 7).³⁷ Yield: 283 mg (87%); white solid; $R_f = 0.51$ (EtOAc:Hexane, 2.0:8.0); m.p. 106-108 °C; ¹H NMR (400 MHz, CDCl_3): δ 7.75-7.73 (d, $J = 8.0$ Hz, 2H), 7.59-7.57 (m, 2H), 7.40-7.36 (t, $J = 8.0$ Hz, 2H), 7.31-7.28 (t, $J = 8.0$ Hz, 2H), 5.34 (br, 1H), 4.39-4.36 (m, 3H), 4.22-4.19 (t, $J = 8.0$ Hz, 1H), 3.74 (s, 3H), 1.42-1.41 (d, $J = 4.8$ Hz, 3H); ¹³C NMR (100 MHz, CDCl_3): δ 173.7, 155.8, 144.0, 141.4, 127.8, 127.2, 125.2, 120.1, 67.1, 52.6, 49.7, 47.2, 18.7; IR (KBr): 3330, 2924, 1747, 1690, 1536, 1267, 1084, 740 cm^{-1} ; HRMS (ESI): m/z [M+H]⁺ calcd for $\text{C}_{19}\text{H}_{19}\text{NO}_4$ 326.1392, found 326.1388.

(DL) Benzyl 2-(tert-butoxycarbonyl)-3-phenylpropanoate (entry 10, Table 7).³⁸ Yield: 319 mg (90%); yellowish solid; $R_f = 0.50$ (EtOAc:Hexane, 2.0:8.0); ¹H NMR (600 MHz, CDCl_3): δ 7.34-7.31 (m, 3H), 7.28-7.26 (d, $J = 8.0$ Hz, 2H), 7.24-7.21 (m, 3H), 7.05-7.01 (m, 2H), 5.16 (s, 2H), 5.05 (br, 1H), 4.54-4.59 (t, $J = 4.0$ Hz, 1H), 3.10-3.07 (d, $J = 8.0$ Hz, 2H), 1.42 (s, 9H); ¹³C NMR (150 MHz, CDCl_3): δ 171.9, 155.2, 136.1, 135.4, 129.5, 128.7, 127.1, 80.0, 67.3, 54.6,

1
2
3 38.4, 28.4; IR (KBr): 3456, 2923, 1732, 1688, 1521, 1223, 1087, 740 cm^{-1} ; HRMS (ESI): m/z
4
5
6 $[M+H]^+$ calcd for $\text{C}_{21}\text{H}_{26}\text{NO}_4$ 356.1862, found 356.1857.
7
8

9 **(L) Benzyl 2-(tert-butoxycarbonyl)-3-phenylpropanoate (entry 11, Table 7).**³⁸ Yield: 316 mg
10 (89%); yellowish solid; $R_f = 0.51$ (EtOAc:Hexane, 2.0:8.0); ^1H NMR (600 MHz, CDCl_3): δ
11 (7.36-7.33 (m, 3H), 7.29-7.27 (d, $J = 8.0$ Hz, 2H), 7.23-7.21 (m, 3H), 7.04-7.02 (m, 2H), 5.14 (s,
12 2H), 5.01 (br, 1H), 4.63-4.61 (t, $J = 4.0$ Hz, 1H), 3.11-3.09 (d, $J = 8.0$ Hz, 2H), 1.41 (s, 9H); ^{13}C
13 NMR (150 MHz, CDCl_3): δ 171.8, 155.19, 135.9, 135.5, 129.5, 128.7, 127.1, 80.1, 67.29, 54.6,
14 38.4, 28.4; IR (KBr): 3456, 2923, 1732, 1688, 1521, 1223, 1087, 740 cm^{-1} ; HRMS (ESI): m/z
15
16
17 $[M+H]^+$ calcd for $\text{C}_{21}\text{H}_{26}\text{NO}_4$ 356.1862, found 356.1857.
18
19
20
21
22
23
24
25

26 ASSOCIATED CONTENT

27 28 29 30 31 Supporting Information

32
33 NMR (^1H and ^{13}C) spectra of 2NBsOXY, the intermediate, and the products in table 3 (entry 1-
34 18); table 4 (entry 1-8); table 6 (entry 1-13); table 7 (entry 1-11); HPLC profiles and ESI spectra
35
36 of peptides and crystal data of the intermediate. This material is available free of charge via the
37
38 internet at <http://pubs.acs.org>
39
40
41
42
43
44
45

46 ACKNOWLEDGEMENTS

47
48 We thank the CIF-IITG for NMR, LC-MS; DST (FIST) for single crystal XRD facility and the
49
50 Department of Science & Technology, India (FAST TRACK scheme, sanction no. SR/FT/CS-
51
52 011/2008) for financial support. D.D., N.B.P., K.T and J.C. thank IIT Guwahati for fellowship.
53
54
55
56
57
58
59
60

REFERENCES

- (1) (a) Greene, W. T.; Wuts, G. P. *Protective Groups in Organic Synthesis*, 4th ed, Wiley, New York, NY, 2007, p 538; (b) Benz, G. *Comprehensive Organic Synthesis*, Trost, B. M.; Fleming, I. Eds, Pergamon: Oxford, 1991, Vol. 6, p 323; (c) Otera, J.; *Esterification*, Wiley-VCH, Weinheim, 2003; (d) Geurts, M.; Poupaert, H. J.; Scriba, G. K. E.; Lambert, D. M. *J. Med. Chem.* **1998**, *41*, 24-30.
- (2) (a) Sheehan, J. C.; Hess, G. P. *J. Am. Chem. Soc.* **1955**, *77*, 1067-1068; (b) Han, S. Y.; Kim, Y. A. *Tetrahedron* **2004**, *60*, 2447-2467; (c) Valeur, E.; Bradley, M. *Chem. Soc. Rev.* **2009**, *38*, 606-631; (d) El-Faham, A.; Albericio, F. *Chem. Rev.* **2011**, *111*, 6557-6602; (e) Bray, B. *L. Rev. Drug Discovery* **2003**, *2*, 587-593; (f) Kent, S. *J. Peptide Sci.* **2003**, *9*, 574-593; (g) W. Zhang, *Tetrahedron* **2003**, *59*, 4475-4489; (h) Najera, C. *Synlett* **2002**, *9*, 1388-1403.
- (3) Carpino, L. A. *J. Am. Chem. Soc.* **1993**, *115*, 4397-4398.
- (4) (a) El-Faham, A.; Subiros-Funosas, R.; Prohens, R.; Albericio, F. *Chem. Eur. J.* **2009**, *15*, 9404-9416; (b) Subirós-Funosas, R.; Khattab, S. N.; Nieto-Rodríguez, L.; El-Faham, A.; Albericio, F. *Aldrichimica Acta* **2013**, *46*, 21-40.
- (5) Subiros-Funosas, R.; Prohens, R.; Barbas, R.; El-Faham, A.; Albericio, F. *Chem. Eur. J.* **2009**, *15*, 9394-9403.
- (6) Wehrstedt, K. D.; Wandrey, P. A.; Heitkamp, D. *J. Hazard. Mater.* **2005**, *126*, 1-7.
- (7) Abdelmoty I.; Albericio, F.; Carpino, L. A.; Foxman, B. M.; Kates, S. A. *Lett. Pept. Sci.* **1994**, *1*, 57-67.
- (8) (a) Palakurthy, N. B.; Dev, D.; Rana, S.; Nadimpally, K. C.; Mandal, B. *Eur. J. Org. Chem.* **2013**, 2627-2633; (b) Dev, D.; Palakurthy, N. B.; Kumar, N.; Mandal, B. *Tetrahedron Lett.* **2013**, *54*, 4397-4400.

- 1
2
3
4 (9) Bodanszky, M. *Peptide Chemistry: A Practical Textbook*, Springer-Verlag, Berlin, 1988, pp.
5
6 116-117.
7
8 (10) El-Faham, A.; Albericio, F. *J. Org. Chem.* **2008**, *73*, 2731-2737.
9
10 (11) Kaminski, Z. J.; Kolesinska, B.; Sabatino, G.; Chelli, M.; Rovero, P.; Blaszczyk, M.; Papini,
11
12 A. M. *J. Am. Chem. Soc.* **2005**, *127*, 16912–16920.
13
14 (12) (a) Weber, G. *Cancer Res.* **1983**, *43*, 3466-3492; (b) Miller, M. J. *Acc. Chem. Res.* **1986**, *19*,
15
16 49-56; (c) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. *Chem. Rev.* **1999**, *99*,
17
18 2735-2776. (d) Palakurthy, N. B.; Dev, D.; Paikaray, S.; Mandal, B. **2013**, *RSC Adv.* **2014**, *4*,
19
20 7952-7958.
21
22 (13) Tenidis, K.; Waldner, M.; Bernhagen, J.; Fischle, W.; Bergmann, M.; Weber, M.; Merkle,
23
24 M. L.; Voelter, W.; Brunner, H.; Kapurniotu, A. *J Mol Biol.* **2000**, *295*, 1055-1071.
25
26 (14) Crescenzi, O.; Tomaselli, S.; Guerrini, R.; Salvadori, S.; Ursi, A. M.; Temussi, P. A.; Picone,
27
28 D. *Eur. J. Biochem.* **2002**, *269*, 5642–5648.
29
30 (15) (a) Ishihara, K.; Nakayama, M.; Ohara, S.; Yamamoto, H. *Tetrahedron* **2002**, *58*, 8179-
31
32 8188; (b) Ishihara, K.; Nakagawa, S.; Sakakura, A. *J. Am. Chem. Soc.* **2005**, *127*, 4168-
33
34 4169; (c) Komura, K.; Ozaki, A.; Ieda, N.; Sugi, Y. *Synthesis* **2008**, 3407-3410; (d) Chen,
35
36 C.; Munot, Y. S. *J. Org. Chem.* **2005**, *70*, 8625-8627; (e). Chakraborti, A. K.; Singh, B.;
37
38 Chankeshwara, S. V.; Patel, A. R. *J. Org. Chem.* **2009**, *74*, 5967-5974.
39
40 (16) Tian, J.; Gao, W. C.; Zhou, D. M.; Zhang, C. *Org. Lett.* **2012**, *14*, 3020-3023.
41
42 (17) Kolesinska, B.; Kaminski, Z. *J. Org. Lett.* **2009** *11*, 765-768.
43
44 (18) Biron, E.; Kessler, H. *J. Org. Chem.* **2005**, *70*, 5183-5189.
45
46 (19) Katritzky, A. R.; Cai, C.; Singh, S. K. *J. Org. Chem.* **2006**, *71*, 3375-3380.
47
48 (20) Ignatenko, V. A.; Deligonul, N.; Viswanathan, R. *Org. Lett.* **2010**, *12*, 3594-3597.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 (21) Nadimpally, K. C.; Thalluri, K.; Palakurthy, N. B. ; Saha, A.; Mandal, B. *Tetrahedron Lett.*
5
6 **2011**, *52*, 2579-2582.
7
8 (22) Kaminski, Z. J.; Kolesinska, B.; Kolesinska, J.; Sabatino, G.; Chelli, M.; Rovero, P.;
9
10 Błaszczuk, M.; Głowka, M. L.; Papini, A. M. *J. Am. Chem. Soc.* **2005**, *127*, 16912-16920.
11
12 (23) Al-Warhi, T. I.; Al-Hazimi, H. M. A.; El-Faham, A.; Albericio, F. *Molecules* **2010**, *15*,
13
14 9403-9417.
15
16
17 (24) Gissot, A.; Volonterio, A.; Zanda, M. *J. Org. Chem.* **2005**, *70*, 6925-6928.
18
19 (25) Khalil, E. M.; Angelis, J. D.; Cole, P. A. *J. Bio. Chem.* **1998**, *273*, 30321-30327.
20
21 (26) Bailen, M. A.; Chinchilla, R.; Dodsworth, D. J.; Najera, C. *Tetrahedron Lett.* **2001**, *42*,
22
23 5013-5016.
24
25
26 (27) Hatano, M; Furuya, Y.; Shimmura, T.; Moriyama, K.; Kamiya, S.; Maki, T.; Ishihara K.
27
28 *Org. Lett.* **2011**, *13*, 426-429.
29
30
31 (28) Damkaci, F.; DeShong, P. *J. Am. Chem. Soc.* **2003**, *125*, 4408-4409.
32
33 (29) Ginisty, M.; Roy, M. N.; Charette, A. B. *J. Org. Chem.* **2008**, *73*, 2542-2547.
34
35 (30) Liu, C.; He, C.; Shi, W.; Chen, M.; Lei, A. *Org. Lett.* **2007**, *9*, 5601-5604.
36
37 (31) Grobelny, Z.; Stolarzewicz, A.; Morejko, B.; Pisarski, W. *Macromolecules* **2006**, *39*, 6832-
38
39 6837.
40
41 (32) Li, Z.; Di, C.; Zhu, Z.; Yu, G.; Li, Z.; Zeng, Q.; Li, Q.; Liu, Y.; Qin, J. *Polymer* **2006**, *47*,
42
43 7889-7899.
44
45 (33) Saturnino, C.; Petrosino, S.; Ligresti, A.; Palladino, C.; Martino, G. D.; Bisogno, T.; Marzo,
46
47 V. D. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1210-1213
48
49 (34) Ward, J. L.; Beale, M. H. *Phytochemistry* **1995**, *38*, 811-816.
50
51 (35) Mamidi, N.; Manna; D. *J. Org. Chem.* **2013**, *78*, 2386-2396.
52
53
54
55
56
57
58
59
60

- 1
2
3
4 (36) Rapolu, S.; Alla, M.; Bommena, V. R.; Murthy, R.; Jain, N.; Bommareddy, V. R.;
5
6 Bommineni, M. R. *Eur. J. Med. Chem.* **2013**, *66*, 91-100.
7
8 (37) Hayashida, O.; Sebo, L.; Rebek, J. *J. Org. Chem.* **2002**, *67*, 8291-8298.
9
10 (38) Wang, Y.; Aleiwi, B. A.; Wang, Q.; Kurosu, M. *Org. Lett.* **2012**, *14*, 18, 4910-4913.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60